WO2023108296A1 - Analogues d'isopropylamine de dérivés de mescaline phosphorylés et sulfonés - Google Patents
Analogues d'isopropylamine de dérivés de mescaline phosphorylés et sulfonés Download PDFInfo
- Publication number
- WO2023108296A1 WO2023108296A1 PCT/CA2022/051846 CA2022051846W WO2023108296A1 WO 2023108296 A1 WO2023108296 A1 WO 2023108296A1 CA 2022051846 W CA2022051846 W CA 2022051846W WO 2023108296 A1 WO2023108296 A1 WO 2023108296A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- sulfate
- compound
- phosphate
- chemical
- Prior art date
Links
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical class COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 title claims abstract description 174
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 title claims abstract description 139
- 150000001875 compounds Chemical class 0.000 claims abstract description 455
- -1 sulfonated mescaline derivative compounds Chemical class 0.000 claims abstract description 89
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 238000009472 formulation Methods 0.000 claims abstract description 33
- 239000003237 recreational drug Substances 0.000 claims abstract description 29
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 11
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 212
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 200
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 146
- 239000000126 substance Substances 0.000 claims description 145
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 123
- 102000005962 receptors Human genes 0.000 claims description 121
- 108020003175 receptors Proteins 0.000 claims description 121
- 238000006243 chemical reaction Methods 0.000 claims description 114
- 229910052757 nitrogen Inorganic materials 0.000 claims description 112
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 109
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 claims description 79
- 125000003051 glycosyloxy group Chemical group 0.000 claims description 78
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 claims description 72
- 125000002252 acyl group Chemical group 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 125000000623 heterocyclic group Chemical group 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 66
- 150000003839 salts Chemical class 0.000 claims description 57
- 150000001768 cations Chemical class 0.000 claims description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 229910019142 PO4 Inorganic materials 0.000 claims description 35
- 238000003786 synthesis reaction Methods 0.000 claims description 30
- 239000010452 phosphate Substances 0.000 claims description 27
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 26
- 238000001727 in vivo Methods 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 150000001450 anions Chemical class 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000000144 pharmacologic effect Effects 0.000 claims description 10
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 claims description 10
- 235000011180 diphosphates Nutrition 0.000 claims description 9
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 7
- 229910001424 calcium ion Inorganic materials 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims description 6
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 claims description 6
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 claims description 6
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 claims description 5
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 claims description 5
- YADJFRGSGWGMNH-UHFFFAOYSA-N [chloro(phenylmethoxy)phosphoryl]oxymethylbenzene Chemical compound C=1C=CC=CC=1COP(=O)(Cl)OCC1=CC=CC=C1 YADJFRGSGWGMNH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002243 precursor Substances 0.000 abstract description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 68
- 229910052799 carbon Inorganic materials 0.000 description 50
- 150000001721 carbon Chemical group 0.000 description 45
- 230000027455 binding Effects 0.000 description 42
- 230000000694 effects Effects 0.000 description 34
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 208000035475 disorder Diseases 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000002287 radioligand Substances 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 238000003556 assay Methods 0.000 description 26
- 238000001525 receptor binding assay Methods 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 20
- 125000004430 oxygen atom Chemical group O* 0.000 description 19
- 239000013641 positive control Substances 0.000 description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 18
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 12
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 229910001415 sodium ion Inorganic materials 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 238000000159 protein binding assay Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 241000219357 Cactaceae Species 0.000 description 8
- 239000012847 fine chemical Substances 0.000 description 8
- 125000003147 glycosyl group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000002821 scintillation proximity assay Methods 0.000 description 8
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical group CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 101150104779 HTR2A gene Proteins 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- RHOGRSKNWDNCDN-UHFFFAOYSA-N escaline Chemical compound CCOC1=C(OC)C=C(CCN)C=C1OC RHOGRSKNWDNCDN-UHFFFAOYSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 150000002989 phenols Chemical class 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 6
- HYWLMSUAZVDUFW-UHFFFAOYSA-N proscaline Chemical compound CCCOC1=C(OC)C=C(CCN)C=C1OC HYWLMSUAZVDUFW-UHFFFAOYSA-N 0.000 description 6
- 229940075993 receptor modulator Drugs 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 5
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 208000028173 post-traumatic stress disease Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 4
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- 238000003570 cell viability assay Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241001074093 Echinopsis Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241001660159 Trichocereus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003400 hallucinatory effect Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000022821 personality disease Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 229930000044 secondary metabolite Natural products 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- BQBQKSSTFGCRQL-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethoxyphenyl)acetic acid Chemical compound COC1=CC(CC(O)=O)=CC(OC)=C1O BQBQKSSTFGCRQL-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 2
- 241001502529 Echinopsis pachanoi Species 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 101150026303 HEX1 gene Proteins 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 208000027109 Headache disease Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 241000883511 Lophophora williamsii Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 208000035217 Ring chromosome 1 syndrome Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- NSBNXCZCLRBQTA-UHFFFAOYSA-N dibenzyl bis(phenylmethoxy)phosphoryl phosphate Chemical compound C=1C=CC=CC=1COP(OP(=O)(OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)(=O)OCC1=CC=CC=C1 NSBNXCZCLRBQTA-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000003843 furanosyl group Chemical group 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000380 hallucinogen Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- XERRPAGNXOWPFF-UHFFFAOYSA-M iodanium;2,3,4-trimethylpyridine;perchlorate Chemical compound [IH2+].[O-]Cl(=O)(=O)=O.CC1=CC=NC(C)=C1C.CC1=CC=NC(C)=C1C XERRPAGNXOWPFF-UHFFFAOYSA-M 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 238000003328 mesylation reaction Methods 0.000 description 2
- 150000001457 metallic cations Chemical class 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000001979 organolithium group Chemical group 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 229960001779 pargyline Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical class [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000019525 primary metabolic process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- SPCIYGNTAMCTRO-UHFFFAOYSA-N psilocin Chemical class C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 description 2
- 150000003214 pyranose derivatives Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LRYGQMJKMLZKQJ-UHFFFAOYSA-N 2-bromo-1,3-dimethoxy-5-phenylmethoxybenzene Chemical compound COC1=C(Br)C(OC)=CC(OCC=2C=CC=CC=2)=C1 LRYGQMJKMLZKQJ-UHFFFAOYSA-N 0.000 description 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 206010049714 Abdominal migraine Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010001854 Altered state of consciousness Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000030336 Bipolar and Related disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000021500 Breathing-related sleep disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 125000003863 D-allosyl group Chemical group 0.000 description 1
- 125000003131 D-altrosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000003319 D-arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000001763 D-gulosyl group Chemical group C1([C@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000137 D-lyxosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 125000003423 D-mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000003603 D-ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000003474 D-talosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000214 D-xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000032538 Depersonalisation Diseases 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000025967 Dissociative Identity disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000435110 Echinopsis lageniformis Species 0.000 description 1
- 241000435122 Echinopsis terscheckii Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019476 Hemiplegic migraine Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000016619 Histrionic personality disease Diseases 0.000 description 1
- 208000014513 Hoarding disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021403 Illusion Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 125000000841 L-allosyl group Chemical group 0.000 description 1
- 125000003272 L-altrosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@@H](O1)CO)* 0.000 description 1
- 125000003599 L-arabinosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)CO1)* 0.000 description 1
- 125000003677 L-glucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@@H](O)[C@@H](O1)CO)* 0.000 description 1
- 125000001864 L-gulosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@@H](O1)CO)* 0.000 description 1
- 125000001191 L-lyxosyl group Chemical group C1([C@H](O)[C@H](O)[C@@H](O)CO1)* 0.000 description 1
- 125000001234 L-mannosyl group Chemical group C1([C@H](O)[C@H](O)[C@@H](O)[C@@H](O1)CO)* 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- 125000003376 L-ribosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@@H](O1)CO)* 0.000 description 1
- 125000004083 L-talosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O)[C@@H](O1)CO)* 0.000 description 1
- 125000003026 L-xylosyl group Chemical group C1([C@@H](O)[C@H](O)[C@@H](O)CO1)* 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000883508 Lophophora Species 0.000 description 1
- 241000883507 Lophophora diffusa Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003863 Marijuana Abuse Diseases 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 206010027387 Merycism Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000027120 Narcissistic personality disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 235000007612 Peruvian apple Nutrition 0.000 description 1
- 244000136787 Peruvian apple Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 239000012095 PrestoBlue reagent Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000028665 Reactive Attachment disease Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000011390 Rumination Syndrome Diseases 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 208000022804 avoidant personality disease Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- ZVJYSSDFOMJWSE-UHFFFAOYSA-N chloro-bis(phenylmethoxy)phosphane Chemical compound C=1C=CC=CC=1COP(Cl)OCC1=CC=CC=C1 ZVJYSSDFOMJWSE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 208000030964 dependent personality disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006212 diphosphorylation reaction Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000035548 disruptive behavior disease Diseases 0.000 description 1
- 206010013461 dissociative amnesia Diseases 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000002017 heptosyl group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical group 0.000 description 1
- 125000000625 hexosyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 101150075901 htr2 gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000015046 intermittent explosive disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 125000001553 ketosyl group Chemical group 0.000 description 1
- 206010023461 kleptomania Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000027881 multiple personality disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical compound CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- FRCFWPVMFJMNDP-UHFFFAOYSA-N n-propan-2-ylaniline Chemical group CC(C)NC1=CC=CC=C1 FRCFWPVMFJMNDP-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001805 pentosyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 208000023961 pica disease Diseases 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001337 psychedelic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000004645 pyromania Diseases 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/568—Four-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/03—Monoamines
- C07C211/05—Mono-, di- or tri-ethylamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/62—Quaternary ammonium compounds
- C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Definitions
- compositions and methods disclosed herein relate to a chemical compound known as mescaline. Furthermore, the compositions, methods, and uses disclosed herein relate, in particular, to isopropylamine analogues of phosphorylated and sulfonated derivatives of mescaline.
- the biochemical pathways in the cells of living organisms may be classified as being part of primary metabolism, or as being part of secondary metabolism. Pathways that are part of a cell’s primary metabolism are involved in catabolism for energy production or in anabolism for building block production for the cell. Secondary metabolites, on the other hand, are produced by the cell without having an obvious anabolic or catabolic function. It has long been recognized that secondary metabolites can be useful in many respects, including as therapeutic compounds.
- Mescaline (chemical name 3,4,5 trimethoxyphenethylamine), for example, is a secondary metabolite that is naturally produced by certain cactus species belonging to a variety of genera within the plant family of Cactaceae.
- Cactus species which can produce mescaline include, for example, cactus species belonging to the genus Lophophora, including Lophophora williamsii (peyote) and Lophophora diffusa and cactus species belonging to the genus Echinopsis/Trichocereus, including Echinopsis pachanoi/Trichocereus pachanoi (also known as San Pedro), Echinopsis peruviana/Trichocereus peruvianus (also known as Peruvian torch), (Echinopsis lageniformis/Tnchocereus bndgesii/ (also known as Peruvian torch), and Echinopsis lageniformis/Tnchocereus bndgesii/ (also known
- mescaline is a psychoactive compound and is therefore used as a recreational drug.
- Mescaline is also used in Native American religious ceremonies, and for spiritual purposes by Andean indigenous cultures.
- mescaline has been evaluated for its potential in the treatment of addictions, notably alcohol addiction (Bogenschutz, M.P. and Johnson M. W. (2016), Prog, in Neuro- Psychopharmacol. & Biol. Psychiatry 64; 250- 258; Romeu, A.G. et al., (2017), Exp. Clin. Psychopharmacol. 2016 Aug; 24(4): 229-268).
- mescaline Although the toxicity of mescaline is low, adverse side effects, including, for example, panic attacks, paranoia, and psychotic states, sometimes together or individually referred to as “a bad trip”, are not infrequently experienced by mescaline users. Furthermore, mescaline can induce nausea and vomiting.
- the present disclosure relates to mescaline and derivative compounds.
- the present disclosure relates to isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives.
- the present disclosure provides, in at least one embodiment, in accordance with the teachings herein, a chemical compound or salt thereof having the chemical formula (I): wherein, Xi , X2, X3, X4, and Xs are independently or simultaneously H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi, X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two or more of Xi, X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(RS) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring.
- one, two or three of X2, X3 and X4 can be a phosphate group or a sulfate group.
- one, two or three of Xi, X3 and X4 can be a phosphate group or a sulfate group.
- one, two or three of Xi, X2 and X3 can be a phosphate group or a sulfate group.
- one, two or three of Xi, X3 and Xs can be a phosphate group or a sulfate group.
- one, two or three of Xi, X2 and X4 can be a phosphate group or a sulfate group.
- compound (I) can contain one or two sulfate groups but does not contain a phosphate group.
- compound (I) can contain one or two phosphate groups but does not contain a sulfate group.
- compound (I) can contain at least one sulfate group and at least one phosphate group.
- compound (I) can contain one sulfate group and one phosphate group.
- compound (I) can contain two sulfate groups and one phosphate group.
- compound (I) can contain one sulfate group and two phosphate groups.
- compound (I) can contain one sulfate group or one phosphate group.
- compound (I) can contain one sulfate group or one phosphate group, and at least one of Xi, X2, X3, X4, and Xs is an O-alkyl group.
- compound (I) can contain one sulfate group or one phosphate group, and at least one of Xi, X2, X3, X4, and Xs is an O-alkyl group, and Xi, X2, X3, X4, and X5 which are not a sulfate group, a phosphate group, or an O-alkyl group are a hydrogen atom.
- compound (I) can contain one sulfate group or one phosphate group, and one of Xi, X2, X3, X4, and X5 is an O-alkyl group, and Xi , X2, X3, X4, and X5 which are not a sulfate group, a phosphate group, or an O-alkyl group, are a hydrogen atom.
- compound (I) can contain one sulfate group or one phosphate group, two of Xi, X2, X3, X4, and X5 are an O- alkyl group, and Xi, X2, X3, X4, and X5 which are not a sulfate group, a phosphate group, or an O-alkyl group, are a hydrogen atom.
- compound (I) can contain one sulfate group or one phosphate group, wherein one of X2, X3, and X4 are a sulfate or phosphate group, two of X2, X3, and X4 are an O-alkyl group, and Xi and Xs are a hydrogen atom.
- compound (I) can contain one sulfate group or one phosphate group, wherein one of X2, and X3, are a sulfate or phosphate group, two of X2, X3, and X4 are an O-alkyl group, and Xi and X5 are a hydrogen atom.
- compound (I) can contain one phosphate group, wherein one of X2, and X3, is a phosphate group, two of X2, X3, and X4 are an O-alkyl group, and Xi and X5 are a hydrogen atom.
- compound (I) can contain one sulfate group, wherein X3 is a sulfate group, X2, and X4 are an O-alkyl group, and Xi and X5 are a hydrogen atom.
- compound (I) can contain one phosphate group, wherein X3 is a phosphate group, X2, and X4 are an O-alkyl group, and Xi and X5 are a hydrogen atom.
- compound (I) can contain one phosphate group, wherein X2 is a phosphate group, X3, and X4 are an O-alkyl group, and Xi and X5 are a hydrogen atom.
- the O-alkyl group can be a (Ci-C6)-O-alkyl group.
- the O-alkyl group can be a (Ci-C3)-O-alkyl group.
- the O-alkyl group can be a methoxy group (-O-CH3).
- the compound of formula (I) when W is N + (R6)(R7)(Rs), the compound of formula (I) can include a counterbalancing anion to form a salt, wherein the salt is formed by the anion and the nitrogen atom (N + ).
- the sulfate or the phosphate group can be an ionic sulfate or ionic phosphate group, and the compound of formula (I) can be a zwitterionic compound.
- the phosphate or sulfate group in the compound of formula (I), can be an ionic phosphate or ionic sulfate group and forms a phosphate or sulfate salt counterbalanced by a cation.
- the phosphate or sulfate group in the compound of formula (I), can be an ionic phosphate or ionic sulfate group and forms a phosphate or sulfate salt counterbalanced by a monovalent, bivalent, trivalent, or tetravalent cation.
- the phosphate group can be an ionic phosphate group forming a salt with a monovalent cation (Z + ), the formed salt having the formula: HPO Z + .
- the phosphate group can be an ionic phosphate group forming a salt with a monovalent cation (Z + ), the formed salt having the formula: (PO4 2- ) (Z + )2.
- the sulfate group can be an ionic sulfate group forming a salt with a monovalent cation (Z + ), the formed salt having the formula: SCU- Z + .
- the monovalent cation (Z + ) can be selected from Na + , K + , NH4 + , tetra-n-butyl ammonium ([N(C4H9)4] + ), and triethyl ammonium (EtsNH4 + ).
- the phosphate group can be an ionic phosphate group forming a salt with a divalent cation (Z 2+ ), the formed salt having the formula: PO4 2 ' Z 2+ .
- the phosphate group can be an ionic phosphate group forming a salt with a divalent cation (Z 2+ ), the formed salt having the formula (HPO4')2 Z 2+ , wherein the second ionic phosphate group (HPO4‘) is a phosphate substituent of a second molecule of the compound having formula (I).
- the phosphate group can be an ionic sulfate group forming a salt with a divalent cation (Z 2+ ), the formed salt having the formula (SO4')2 Z 2+ , wherein the second ionic sulfate group (SO4-) is a sulfate substituent of a second molecule of the compound having formula (I).
- the divalent cation (Z 2+ ) can be selected from Mg 2+ and Ca 2+ .
- the compound having formula (I) can be selected from the group of chemical compounds having a formula (III); (IV); or (V): wherein in chemical formula (V), Z +/2+ is a mono or divalent cation balancing the negatively charged sulfate group, forming a salt having the formula
- Z + can be selected from Na + , K + , NH4 + , tetra-n-butyl ammonium ([N(C4H9)4] + ), and triethyl ammonium (EtsNH4).
- Z 2+ can be selected from Mg 2+ and Ca 2+ .
- the chemical compound can be selected from (Vb); (V c ); (Vd); (V e ); (Vf); (V g ); and (Vh):
- the compound of formula (I) when W is N + (R6)(R7)(Rs), the compound of formula (I) can comprise a pharmaceutically acceptable anion.
- the present disclosure relates to pharmaceutical and recreational drug formulations comprising isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives.
- the present disclosure provides, in at least one embodiment, a pharmaceutical or recreational drug formulation comprising an effective amount of a chemical compound or salt thereof having the chemical formula (I): wherein, Xi, X2, X3, X4, and X5 are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two of Xi, X2, X3, X4, and Xs are H; and wherein W is -N(R 4 )(R 5 ) or -N + (
- R 4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R 4 , and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R? and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring, together with a pharmaceutically acceptable excipient, diluent, or carrier.
- the present disclosure relates to methods of treatment of psychiatric disorders. Accordingly, the present disclosure further provides, in one embodiment, a method for treating a psychiatric disorder, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising a chemical compound or salt thereof having the chemical formula (I): wherein,
- Xi , X2, X3, X 4 , and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X 4 , and Xs are a phosphate group or a sulfate group, and two of Xi , X2, X3, X 4 , and Xs are H; and wherein
- W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R 4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R 4 , and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and R 8 are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and R 8 are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring, and wherein the pharmaceutical formulation is administered in an effective amount to treat the psychiatric disorder in the subject.
- the compound having formula (I) upon administration can interact with a receptor in the subject to thereby modulate the receptor and exert a pharmacological effect.
- the receptor can be a 5- HTIA receptor, or a 5-HT2A receptor.
- the disorder can be a 5- HTIA receptor mediated disorder, or a 5-HT2A receptor mediated disorder.
- the compound having formula (I) upon administration can interact with a 5-HTIA receptor and a 5-HT2A receptor in the subject to thereby modulate both the 5-HTIA receptor and the 5- HT 2 A receptor and exert a pharmacological effect.
- the compound having formula (I) upon administration can interact with a 5-HT2A receptor in the subject to thereby modulate the 5-HT2A receptor without modulating the 5-HTIA receptor and exert a pharmacological effect.
- the present disclosure provides, in at least one embodiment, a method for modulating a receptor selected from 5-HTIA receptor, and a 5-HT2A receptor with a chemical compound or salt thereof having formula (I): wherein,
- Xi, X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two of Xi, X2, X3, X4, and Xs are H; and wherein W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R 4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R 4 , and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R? and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring, under reaction conditions sufficient to modulate the 5-HTIA receptor, or 5-HT2A receptor.
- the reaction conditions can be in vitro reaction conditions.
- the reaction conditions can be in vivo reaction conditions, and the in vivo reaction conditions comprise administering an effective amount of the chemical compound to a human or animal subject possessing a 5-HT2A receptor and a 5-HTIA receptor, wherein the 5-HT2A receptor is modulated and the 5-HTIA receptor is not modulated.
- the reaction conditions can be in vivo reaction conditions, and the in vivo reaction conditions comprise administering an effective amount of the chemical compound to a human or animal subject possessing a 5-HT2A receptor and a 5-HTIA receptor, wherein both the 5- HT2A and the 5-HTIA receptor are modulated.
- the reaction conditions can be in vivo reaction conditions.
- the present disclosure relates to methods of making isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives. Accordingly, in one aspect, the present disclosure provides, in at least one embodiment, a method of making isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives, the method comprising reacting a phosphor-oxidous compound or a sulfur-oxidous compound with a chemical compound having the formula (II): wherein,
- Xi , X2, X3, X4, and Xs are H, a reactive group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi, X2, X3, X4, and Xs are a reactive group, and two of Xi, X2, X3, X4, and X5 are H; and wherein
- W is -CH2CH(CH 3 )N(R 4 )(R5) or -CH2CH(CH 3 )N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or to thereby form the isopropylamine analogue of a phosphorylated and sulfonated mescaline derivative, the formed isopropylamine analogue of a phosphorylated and sulfonated mescaline derivatives having the chemical formula (I): wherein,
- Xi , X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two of Xi, X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring.
- the reactive group can be a hydroxy group and the sulfur-oxidous compound can be a pyridinium sulfur trioxide or tetrabutylammonium hydrogen sulfate.
- the reactive group can be a hydroxy group and the phosphor-oxidous compound can be tetra-O-benzyl pyrophosphate or dibenzyl chlorophosphate.
- the method can comprise the performance of at least one of the chemical reactions depicted in FIG. 11 or FIG. 12, under reaction conditions sufficient to form the chemical compound having formula (I).
- the compound having chemical formula (I) can be a compound having the chemical formula (III): and the least one chemical synthesis reaction is selected from chemical reaction (d); (c) and (d); (b), (c), and (d); and (a), (b), (c), and (d), depicted in FIG. 11 , wherein the least one chemical synthesis reaction is conducted under reaction conditions sufficient to form the chemical compound having formula (III).
- the compound having chemical formula (I) can be a compound having the chemical formula (IV): and the least one chemical synthesis reaction is selected from chemical reaction (f); (e) and (f); (d), (e), and (f); (c), (d), (e), and (f); (b), (c), (d) (e), and (f); and (a), (b), (c), (d) (e), and (f), depicted in FIG. 12, wherein the least one chemical synthesis reaction is conducted under reaction conditions sufficient to form the chemical compound having formula (IV).
- the compound having chemical formula (I) can be a compound having the chemical formula (V c ): and the least one chemical synthesis reaction is selected from chemical reaction (d); (c) and (d); (b), (c), and (d); and (a), (b), (c), and (d), depicted in FIG. 12, wherein the least one chemical synthesis reaction is conducted under reaction conditions sufficient to form the chemical compound having formula (V c ).
- the present disclosure provides, in at least one embodiment, a use of a chemical compound or salt thereof having chemical formula (I): wherein,
- Xi , X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two of Xi , X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring, in the manufacture of a pharmaceutical or recreational drug formulation.
- the manufacture can comprise formulating the chemical compound with an excipient, diluent, or carrier.
- the present disclosure provides, in at least one embodiment, a use of a chemical compound or salt thereof having chemical formula (I): wherein,
- Xi , X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and Xs are a phosphate group or a sulfate group, and two of Xi , X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R 4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R 4 , and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R? and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring, together with a diluent, carrier, or excipient as a pharmaceutical or recreational drug formulation.
- FIG. 1 depicts the chemical structure of mescaline, and identifies a phenyl portion, comprising a substituted phenyl group, and an ethylamine portion of the compound.
- FIG. 2 depicts a certain mescaline derivative prototype structure.
- the prototype structure contains a phenyl portion, comprising a substituted phenyl group, and an isopropylamine portion, as indicated.
- Carbon atoms have been numbered Ci, C2, C3, etc. to indicate their position in the phenyl portion or isopropylamine portion, respectively.
- Ci Ci carbon
- C2, C3, etc. Carbon atoms
- the isopropylamine chain extends from the Ci carbon of the phenyl group, and, for example, that the amine group extends from the C2 carbon of the isopropylamine portion.
- certain compounds may be named in accordance with the same.
- FIGS. 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H, 3I, 3J, and 3K depict the chemical structures of certain example isopropylamine mescaline derivatives, notably isopropylamine analogues of 3,4,5-X2,X3,X4-mescaline derivatives (FIGS. 3A, 3B), isopropylamine analogues of 2,4,5-XIXS,X4 mescaline derivatives (FIGS. 3C, 3D), isopropylamine analogues of 2,3,4-XIX2,XS mescaline derivatives (FIGS.
- Xi, X2, X 3 , X 4 , and X 5 are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, and 1 to 3 of Xi, X2, X3, X4, and X5 are a phosphate group or a sulfate group.
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring (FIGS. 3A, 3C, 3E, 3G, 3I), or (ii) Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring, wherein the positively charged nitrogen atom in compound is balanced by M a negatively charged anion (FIGS. 3B, 3D, 3F, 3H, 3 J), or by a negatively charged sulfate group (FIG. 3K).
- FIGS. 4A, 4B, 4C, 4D, 4E, 4F, 4G, 4H, 4I, 4J, 4K, 4L, 4M, 4N, 40, 4P, 4Q, 4R, 4S, 4T, 4U, and 4V depict the chemical structures of certain example isopropylamine analogues of mescaline derivatives, notably, an isopropylamine analogue of a 2-sulfonyl-4,6-X3,Xs mescaline derivative (FIG. 4A), an isopropylamine analogue of a 2-phospho-4,6-X3,Xs mescaline derivative (FIG.
- an isopropylamine analogue of a 2,4-di- sulfonyl-6-X5-mescaline derivative (FIG. 4G)
- an isopropylamine analogue of a 2,4-di-phospho-6-Xs mescaline derivative (FIG. 4H)
- an isopropylamine analogue of a 2,6-di-sulfonyl-4-X3 mescaline derivative (FIG. 4I)
- an isopropylamine analogue of a 2,6-di-phospho-4-X3 mescaline derivative (FIG.
- an isopropylamine analogue of a 2-Xi-4,6-di-sulfonyl mescaline derivative (FIG. 4K), an isopropylamine analogue of a 2-Xi-4,6-di-phospho mescaline derivative (FIG. 4L), an isopropylamine analogue of a 2-Xi-4-phospho-6-sulfonyl mescaline derivative (FIG. 4M), an isopropylamine analogue of a 2-Xi-4-sulfonyl-6-phospho mescaline derivative (FIG.
- an isopropylamine analogue of a 2-sulfonyl-4-X3- 6-phospho-mescaline derivative (FIG. 40), an isopropylamine analogue of a 2- phospho-4-X3-6-sulfonyl mescaline derivative (FIG. 4P), an isopropylamine analogue of a 2,4-6-tri-phospho mescaline derivative (FIG. 4Q), an isopropylamine analogue of a 2,4-6-tri-sulfonyl mescaline derivative (FIG. 4R), an isopropylamine analogue of a 2-sulfonyl-4,6-di-phospho mescaline derivative (FIG.
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring.
- FIGS. 5A, 5B, 5C, 5D, 5E, 5F, 5G, 5H, 5I, 5J, 5K, and 5L depict the chemical structures of certain example isopropylamine analogues of mescaline derivatives, notably, an isopropylamine analogue of a 4-sulfonyl-2,6-dihydroxy mescaline derivative (FIG. 5A), an isopropylamine analogue of a 4-phospho-2,6- di-hydroxy mescaline derivative (FIG. 5B), an isopropylamine analogue of a 2,6- di-methoxy-4-sulfonyl mescaline derivative (FIG.
- FIGS. 5A, 5B, 5C, 5D, 5E, 5F, 5G, 5H, 5I, 5J, 5K, and 5L depict the chemical structures of certain example isopropylamine analogues of mescaline derivatives, notably, an isopropylamine
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring.
- FIGS. 6A, 6B, 6C, 6D, 6E, 6F, 6G, and 6H depict the chemical structures of certain example isopropyl analogues of mescaline derivatives, notably, an isopropylamine analogue of a 2-ethoxy-4-sulfonyl-6-hydroxy mescaline derivative, wherein R4 and Rs, are hydrogen atoms (FIG. 6A), an isopropylamine analogue of a 2-ethoxy-4-phospho-6-hydroxy mescaline derivative, wherein R4 and Rs, are hydrogen atoms (FIG.
- FIG. 6B an isopropylamine analogue of a 2-ethoxy-4-sulfonyl-6-hydroxy mescaline derivative, wherein R4 and Rs, are ethyl groups
- FIG. 6C an isopropylamine analogue of a 2-ethoxy-4- phospho-6-hydroxy mescaline derivative, wherein R4 and Rs, are methyl groups
- FIG. 6D an isopropylamine analogue of a 2-ethoxy-4-sulfonyl-6-hydroxy mescaline derivative, wherein R4 is a hydrogen atom and Rs, is an ethyl group
- FIGS. 7A, 7B, 7C, 7D, 7E, 7F, 7G, and 7H depict the chemical structures of certain example isopropylamine mescaline derivatives, notably, an isopropylamine analogue of a 2-ethoxy-4-sulfonyl-6-hydroxy mescaline derivative, wherein Re, R7 and Rs are hydrogen atoms (FIG. 7A), an isopropylamine analogue of a 2-ethoxy-4-phospho-6-hydroxy mescaline derivative, wherein Re, R? and Rs are hydrogen (FIG.
- FIGS. 8A, 8B, 8C, 8D, 8E, 8F, 8G, 8H, 81, 8J, 8K, 8L, 8M, 8N, 80, 8P, 8Q, 8R, 8S, and 8T depict the chemical structures of certain example isopropylamine mescaline derivatives, notably and an isopropylamine analogue of a 2-ethoxy-4-sulfonyl-6-hydroxy mescaline derivative, wherein R4 and Rs are joined forming a 6-membered heterocyclic ring wherein a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by an oxygen atom to form a morpholinyl ring (FIG.
- FIGS. 9A, 9B, 9C, 9D, 9E, 9F, and 9G depict the chemical structures of certain example isopropylamine mescaline derivatives, notably, an isopropylamine analogue of a 2-hydroxy-4,6-X3, Xs mescaline derivative (FIG. 9A), an isopropylamine analogue of a 2,6-XiXs-4-hydroxy mescaline derivative (FIG. 9B), an isopropylamine analogue of a 2,4-Xi ,X3-6-hydroxy-mescaline derivative (FIG. 9C), an isopropylamine analogue of a 2,4-di-hydroxy-6-Xs-mescaline derivative (FIG.
- FIGS. 9A, 9B, 9C, 9D, 9E, 9F, and 9G depict the chemical structures of certain example isopropylamine mescaline derivatives, notably, an isopropylamine analogue of a 2-hydroxy-4,6
- Xi, X3 and Xs which are not a hydroxy group can be an O-alkyl group, an O-acyl group, a hydrogen atom, or a glycosyloxy group.
- R4 and Rs can be an alkyl group, an acyl group, or a hydrogen, atom, or R4 and Rs can be joined to from a heterocyclic ring.
- FIGS. 10A, 10B, and 10C depict certain example synthesis pathways to make sulfate- and phosphate-functionalized isopropylamine mescaline derivatives, notably an example synthesis of an example single sulfate- or phosphate-functionalized isopropylamine mescaline derivative (FIGS. 10A and 10B).
- FIG. 10B further shows an example of synthesis method of an isopropylamine mescaline derivative with modifications on the amine group.
- FIG. 10C depicts an example synthesis of making example isopropylamine mescaline derivatives containing multiple sulfate or phosphate groups.
- FIG. 11 depicts another example synthesis pathway for an example single phosphorylated mescaline derivative compound (denoted as compound 5) according to the present disclosure. Individual chemical reactions in the example synthesis pathway are denoted as (a), (b), (c), and (d).
- FIG. 12 depicts another example synthesis pathway for another example single phosphorylated mescaline derivative compound (denoted as compound 8) and a single sulfonated mescaline derivative (denoted as compound 6) according to the present disclosure.
- Individual chemical reactions in the example synthesis pathway are denoted as (a), (b), (c), (d), (e), and (f).
- FIG. 13A a cell viability assay
- FIG. 13B a radioligand 5-HTIA receptor binding assay using 2C-B (positive control)
- FIG. 13C a radioligand 5- HTIA receptor binding assay using MDMA (positive control)
- FIG. 13D a radioligand 5-HTIA receptor binding assay using mescaline
- FIG. 13E a radioligand 5-HT IA receptor binding assay using escaline (positive control)
- FIG. 13E a radioligand 5-HTIA receptor binding assay using proscaline (positive control)
- FIG. 13F a radioligand 5-HTIA receptor binding assay using tryptophan (negative control) (FIG. 13G); a radioligand 5-HTIA receptor binding assay using compound (III) (FIG. 13H); a radioligand 5-HT2A receptor binding assay using 2C- B (positive control) (FIG. 131); a radioligand 5-HT2A receptor binding assay using MDMA (positive control) (FIG. 13J); a radioligand 5-HT2A receptor binding assay using mescaline (positive control) (FIG. 13K); a radioligand 5-HT2A receptor binding assay using escaline (positive control) (FIG.
- FIG. 13L a radioligand 5-HT2A receptor binding assay using proscaline (positive control)
- FIG. 13M a radioligand 5-HT2A receptor binding assay using proscaline
- FIG. 13N a radioligand 5-HT2A receptor binding assay using tryptophan
- FIG. 130 a radioligand 5-HT2A receptor binding assay using compound (III)
- FIGS. 14A, 14B, and 14C depict various graphs representing certain experimental results, notably, graphs obtained in the performance of experimental assays to evaluate the efficacy of an example compound having chemical formula
- FIGS. 15A, 15B, and 15C depict various graphs representing certain experimental results, notably, graphs obtained in the performance of experimental assays to evaluate the efficacy of an example compound having chemical formula (Vc), notably, a cell viability assay (FIG. 15A); a radioligand 5-HTIA receptor binding assay using compound (V c ) (FIG. 15B); and a radioligand 5-HT2A receptor binding assay using compound (V c ) (FIG. 15C).
- compositions, systems or processes will be described below to provide an example of an embodiment of each claimed subject matter. No embodiment described below limits any claimed subject matter and any claimed subject matter may cover processes, compositions or systems that differ from those described below.
- the claimed subject matter is not limited to compositions, processes or systems having all of the features of any one composition, system or process described below or to features common to multiple or all of the compositions, systems or processes described below. It is possible that a composition, system, or process described below is not an embodiment of any claimed subject matter.
- compositions, system or process described below may be the subject matter of another protective instrument, for example, a continuing patent application, and the applicant(s), inventor(s) orowner(s) do not intend to abandon, disclaim or dedicate to the public any such subject matter by its disclosure in this document.
- compositions, systems or processes will be described below to provide an example of an embodiment of each claimed subject matter. No embodiment described below limits any claimed subject matter and any claimed subject matter may cover processes, compositions or systems that differ from those described below.
- the claimed subject matter is not limited to compositions, processes or systems having all of the features of any one composition, system or process described below or to features common to multiple or all of the compositions, systems or processes described below. It is possible that a composition, system, or process described below is not an embodiment of any claimed subject matter.
- compositions, system or process described below may be the subject matter of another protective instrument, for example, a continuing patent application, and the applicant(s), inventor(s) orowner(s) do not intend to abandon, disclaim or dedicate to the public any such subject matter by its disclosure in this document.
- any range of values described herein is intended to specifically include the limiting values of the range, and any intermediate value or sub-range within the given range, and all such intermediate values and sub-ranges are individually and specifically disclosed (e.g., a range of 1 to 5 includes 1 , 1.5, 2, 2.75, 3, 3.90, 4, and 5).
- other terms of degree such as “substantially” and “approximately” as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of the modified term if this deviation would not negate the meaning of the term it modifies.
- mescaline refers to a chemical compound having the structure set forth in FIG. 1. It is noted that mescaline is also known in the art as 3,4,5 trimethoxyphenethylamine. It is further noted that mescaline includes a phenyl portion comprising a substituted phenyl group, and an ethylamine portion, as shown in FIG. 1.
- the term “mescaline derivative prototype structure” refers to the chemical structure shown in FIG. 2.
- the mescaline derivatives disclosed herein include the mescaline derivative prototype structure shown in FIG. 2, wherein various atoms may be substituted, as herein described.
- the prototype structure comprises a phenyl portion and an isopropylamine portion (instead of an ethylamine portion as is the case for mescaline, see: FIG. 1).
- specific carbon atoms in the mescaline derivative prototype structure are numbered.
- specific carbon atoms in the phenyl portion of the prototype structure are numbered separately from the carbon atoms in the isopropylamine portion.
- Xi, X2, X3, X 4 , and X5 are independently or simultaneously H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi, X2, X3, X 4 , and X5 are a phosphate group or a sulfate group, and two or more of Xi, X2, X3, X 4 , and X5 are H; and wherein
- W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R 4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R 4 , and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R? and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring.
- sulfate group refers to a molecule containing one atom of sulfur covalently bonded to four atoms of oxygen, and having the chemical formula SO 4 2- .
- One of the oxygen atoms may be chemically bonded to another atom, resulting in the sulfate group having a single negative charge.
- Other entities bonded to the sulfate group may be referred to as sulfonated entities, e.g., a sulfonated mescaline derivative, and compounds bonded to the sulfate group may be said to carry a sulfonyl group.
- phosphate group refers to a molecule containing one atom of phosphorus covalently bonded to four oxygen atoms (three single bonds and one double bond), and having the chemical formula PO 4 3- .
- One of the oxygen atoms may be chemically bonded to another atom, resulting in the phosphate group having a double negative charge (-OPOs 2- ).
- one or two of the oxygen atoms may be bonded to a hydrogen atom to form HPO 4 2- (and having a single negative charge when so bonded), or H2PO4 (and having no charge when so bonded), respectively.
- Other entities bonded to the phosphate group may be referred to as phosphorylated entities, e.g., a phosphorylated mescaline derivative, and compounds bonded to the phosphate group may be said to carry a phospho group.
- hydroxy group refers to a molecule containing one atom of oxygen bonded to one atom of hydrogen, and having the chemical formula -OH. A hydroxy group through its oxygen atom may be chemically bonded to another entity.
- glycosylated refers to a saccharide group, such as a mono-, di-, tri- oligo- or a poly-saccharide group, which can be or has been bonded from its anomeric carbon either in the pyranose or furanose form, either in the a or the p conformation.
- the bonded saccharide group, inclusive of the oxygen atom may be referred to herein as a “glycosyloxy” group.
- Example monosaccharide groups include, but are not limited to, a pentosyl, a hexosyl, or a heptosyl group.
- the glycosyloxy group may also be substituted with various groups. Such substitutions may include lower alkyl, lower alkoxy, acyl, carboxy, carboxyamino, amino, acetamido, halo, thio, nitro, keto, and phosphatyl groups, wherein the substitution may be at one or more positions on the saccharide. Included in the term glycosyl are further stereoisomers, optical isomers, anomers, and epimers of the glycosyloxy group.
- a hexose group for example, can be either an aldose or a ketose group, can be of D- or L- configuration, can assume either an a- or p- conformation, and can be a dextro- or levo-rotatory with respect to plane-polarized light.
- Example glycosyloxy and glycosyl groups further include, glucosyl group, glucuronic acid group, a galactosyl group, a fucosyl group, a xylose group, an arabinose group, and a rhamnose group.
- alkyl group refers to a hydrocarbon group arranged in a chain having the chemical formula -CnH2n+i.
- Alkyl groups include, without limitation, methyl groups (-CH3), ethyl groups (-C2H5), propyl groups (-C3H7) and butyl groups (-C4H9).
- O-alkyl group refers to a hydrocarbon group arranged in a chain having the chemical formula -O-CnH2n+i.
- O-Alkyl groups include, without limitation, O-methyl groups (-O-CH3), O-ethyl groups (-O-C2H5), O-propyl groups (-O-C3H7) and O-butyl groups (-O-C4H9).
- acyl group refers to a carbon atom double bonded to an oxygen and single bonded to an alkyl group. The carbon atom further can be bonded to another entity.
- O-acyl group refers to an acyl group in which the carbon atom is single bonded to an additional oxygen atom.
- the additional oxygen atom can be bonded to another entity.
- hetero refers to a saturated or partially saturated or aromatic cyclic group, in which one or more (for example, one or two) ring atoms are a heteroatom selected from N, O, or S, the remaining ring atoms being C. Included are, for example, (C3-C20), (C3-C10), and (Cs-Ce) cyclic groups comprising one or two hetero atoms selected from O, S, or N.
- aryl group refers to an aromatic ring compound in which at least one hydrogen compound has been removed from the aromatic ring to permit the bonding of a carbon atom in the aromatic ring to another entity.
- the aryl groups can optionally be a substituted Ce-Cu-aryl.
- the aryl group can further optionally be substituted Ce-C -aryl, or phenyl.
- Further aryl groups include phenyl, naphthyl, tetrahydronaphthyl, phenanthrenyl, biphenylenyl, indanyl, or indenyl and the like.
- phosphor-oxidous compound refers to a compound including at least one phosphorus atom and a plurality of oxygen atoms, which when reacted with a reactive group, such as a hydroxy group, can form a phosphate group, and include, for example, tetra-O-benzyl pyrophosphate, phosphorus pentoxide (P2O5), and phosphorus oxychloride/trimethylphosphate.
- sulfur-oxidous compound refers to a compound including at least one sulfur atom and a plurality of oxygen atoms, which when reacted with a reactive group, such as a hydroxy group, can form a sulfate group, and include, for example, pyridinium sulfur trioxide, and trimethylamine-sulfur trioxide.
- receptor refers to a protein present on the surface of a cell (such as a human cell, for example, a central nervous system (CNS) cell, a hypothalamus cell, a neocortex cell), or in a cell not associated with a cellular surface (e.g., a soluble receptor) capable of mediating signaling to and/or from the cell, or within the cell and thereby affect cellular physiology.
- a cell such as a human cell, for example, a central nervous system (CNS) cell, a hypothalamus cell, a neocortex cell
- a cell not associated with a cellular surface e.g., a soluble receptor
- Example receptors include, 5-HTIA receptors, 5-HTI B receptors, 5-HT2A receptors, and “5- HT2B receptors”, and so on.
- signaling refers to a response in the form of a series of chemical reactions which can occur when a molecule, including, for example, the mescaline derivatives disclosed herein, interacts with a receptor. Signaling generally proceeds across a cellular membrane and/or within a cell, to reach a target molecule or chemical reaction, and results in a modulation in cellular physiology. Thus, signaling can be thought of as a transduction process by which a molecule interacting with a receptor can modulate cellular physiology, and, furthermore, signaling can be a process by which molecules inside a cell can be modulated by molecules outside a cell.
- receptor binding assays for example, radioligand binding assays, such as e.g., [ 3 H]ketanserin assays may be used to evaluate receptor 5- HT 2 A receptor activity
- competition assays for example, competition assays, and saturation binding assays, and the like.
- 5-HT2A receptor refers to a subclass of a family of receptors for the neurotransmitter and peripheral signal mediator serotonin. 5-HT2A receptors can mediate a plurality of central and peripheral physiologic functions of serotonin. Central nervous system effects can include mediation of hallucinogenic effects of hallucinogenic compounds.
- the term “modulating 5-HT2A receptors”, as used herein, refers to the ability of a compound disclosed herein to alter the function of 5-HT2A receptors.
- a 5-HT2A receptor modulator may activate the activity of a 5-HT2A receptor, may activate or inhibit the activity of a 5-HT2A receptor depending on the concentration of the compound exposed to the 5-HT2A receptor, or may inhibit the activity of a 5- HT 2 A receptor. Such activation or inhibition may be contingent on the occurrence of a specific event, such as activation of a signal transduction pathway, and/or maybe manifest only in particular cell types.
- modulating 5-HT2A receptors also refers to altering the function of a 5-HT2A receptor by increasing or decreasing the probability that a complex forms between a 5-HT2A receptor and a natural binding partner to form a multimer.
- a 5-HT2A receptor modulator may increase the probability that such a complex forms between the 5-HT2A receptor and the natural binding partner, may increase or decrease the probability that a complex forms between the 5-HT2A receptor and the natural binding partner depending on the concentration of the compound exposed to the 5-HT2A receptor, and or may decrease the probability that a complex forms between the 5-HT2A receptor and the natural binding partner.
- 5-HT2A receptor-mediated disorder refers to a disorder that is characterized by abnormal 5-HT2A receptor activity.
- a 5-HT2A receptor-mediated disorder may be completely or partially mediated by modulating 5-HT2A receptors.
- a 5-HT2A receptor-mediated disorder is one in which modulation of 5-HT2A receptors results in some effect on the underlying disorder e.g., administration of a 5-HT2A receptor modulator results in some improvement in at least some of the subjects being treated.
- 5-HTIA receptor refers to a subclass of a family of receptors for the neurotransmitter and peripheral signal mediator serotonin.
- 5-HTIA receptors can mediate a plurality of central and peripheral physiologic functions of serotonin.
- Ligand activity at 5-HTIA is generally not associated with hallucination, although many hallucinogenic compounds are known to modulate 5-HTIA receptors to impart complex physiological responses (Inserra et al., 2020, Pharmacol. Rev. 73: 202).
- the term “modulating 5-HTIA receptors”, as used herein, refers to the ability of a compound disclosed herein to alter the function of 5-HTi A receptors.
- a 5-HTIA receptor modulator may activate the activity of a 5-HTIA receptor, may activate or inhibit the activity of a 5-HTIA receptor depending on the concentration of the compound exposed to the 5-HTIA receptor, or may inhibit the activity of a 5- HTIA receptor. Such activation or inhibition may be contingent on the occurrence of a specific event, such as activation of a signal transduction pathway, and/or maybe manifest only in particular cell types.
- modulating 5-HTIA receptors also refers to altering the function of a 5-HTIA receptor by increasing or decreasing the probability that a complex forms between a 5-HTIA receptor and a natural binding partner to form a multimer.
- a 5-HTIA receptor modulator may increase the probability that such a complex forms between the 5-HTIA receptor and the natural binding partner, may increase or decrease the probability that a complex forms between the 5-HTIA receptor and the natural binding partner depending on the concentration of the compound exposed to the 5-HTi A receptor, and or may decrease the probability that a complex forms between the 5-HTIA receptor and the natural binding partner.
- 5-HTIA receptor-mediated disorder refers to a disorder that is characterized by abnormal 5-HTIA receptor activity.
- a 5-HTIA receptor-mediated disorder may be completely or partially mediated by modulating 5-HTIA receptors.
- a 5-HTIA receptor-mediated disorder is one in which modulation of 5-HTIA receptors results in some effect on the underlying disorder e.g., administration of a 5-HTIA receptor modulator results in some improvement in at least some of the subjects being treated.
- pharmaceutical formulation refers to a preparation in a form which allows an active ingredient, including a psychoactive ingredient, contained therein to provide effective treatment, and which does not contain any other ingredients which cause excessive toxicity, an allergic response, irritation, or other adverse response commensurate with a reasonable risk/benefit ratio.
- the pharmaceutical formulation may contain other pharmaceutical ingredients such as excipients, carriers, diluents, or auxiliary agents.
- the term “recreational drug formulation”, as used herein, refers to a preparation in a form which allows a psychoactive ingredient contained therein to be effective for administration as a recreational drug, and which does not contain any other ingredients which cause excessive toxicity, an allergic response, irritation, or other adverse response commensurate with a reasonable risk/benefit ratio.
- the recreational drug formulation may contain other ingredients such as excipients, carriers, diluents, or auxiliary agents.
- the term “effective for administration as a recreational drug”, as used herein, refers to a preparation in a form which allows a subject to voluntarily induce a psychoactive effect for non-medical purposes upon administration, generally in the form of self-administration.
- the effect may include an altered state of consciousness, satisfaction, pleasure, euphoria, perceptual distortion, or hallucination.
- the term “effective amount”, as used herein, refers to an amount of an active agent, pharmaceutical formulation, or recreational drug formulation, sufficient to induce a desired biological or therapeutic effect, including a prophylactic effect, and further including a psychoactive effect. Such effect can include an effect with respect to the signs, symptoms or causes of a disorder, or disease or any other desired alteration of a biological system.
- the effective amount can vary depending, for example, on the health condition, injury stage, disorder stage, or disease stage, weight, or sex of a subject being treated, timing of the administration, manner of the administration, age of the subject, and the like, all of which can be determined by those of skill in the art.
- treating and “treatment”, and the like, as used herein, are intended to mean obtaining a desirable physiological, pharmacological, or biological effect, and includes prophylactic and therapeutic treatment.
- the effect may result in the inhibition, attenuation, amelioration, or reversal of a sign, symptom orcause of a disorder, or disease, attributable to the disorder, or disease, which includes mental and psychiatric diseases and disorders.
- Clinical evidence of the prevention or treatment may vary with the disorder, or disease, the subject, and the selected treatment.
- pharmaceutically acceptable refers to materials, including excipients, carriers, diluents, counterions or auxiliary agents, that are compatible with other materials in a pharmaceutical or recreational drug formulation and within the scope of reasonable medical judgement suitable for use in contact with a subject without excessive toxicity, allergic response, irritation, or other adverse response commensurate with a reasonable risk/benefit ratio.
- substantially pure and “isolated”, as may be used interchangeably herein describe a compound, e.g., a mescaline derivative, which has been separated from components that naturally accompany it.
- a compound is substantially pure when at least 60%, more preferably at least 75%, more preferably at least 90%, 95%, 96%, 97%, or 98%, and most preferably at least 99% of the total material (by volume, by wet or dry weight, or by mole percent or mole fraction) in a sample is the compound of interest.
- Purity can be measured by any appropriate method, e.g., in the case of polypeptides, by chromatography, gel electrophoresis or HPLC analysis.
- the present disclosure relates to mescaline derivatives.
- the present disclosure provides novel isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives.
- the herein provided compositions exhibit functional properties which deviate from the functional properties of mescaline.
- the isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives can exhibit pharmacological properties which deviate from mescaline, including, for example, with respect to interaction the derivatives with receptors, such as the 5-HTia receptor or 5-HT2a receptor.
- the isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives may exhibit physico-chemical properties which differ from mescaline.
- the isopropylamine mescaline derivatives may exhibit superior solubility in a solvent, for example, an aqueous solvent.
- the isopropylamine mescaline derivatives in this respect are useful in the formulation of pharmaceutical and recreational drug formulations.
- the isopropylamine mescaline derivatives of the present disclosure can conveniently be synthetically produced.
- the practice of this method avoids the extraction of mescaline from cactus plants and the performance of subsequent chemical reactions to achieve the isopropylamine analogues of phosphorylated and sulfonated mescaline of the present disclosure. Furthermore, the growth of cactus plants can be avoided thus limiting the dependence on climate and weather, and potential legal and social challenges associated with the cultivation of cactus plants containing psychoactive compounds.
- the method can efficiently yield substantial quantities of isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives.
- the present disclosure provides derivatives of a compound known as mescaline of which the chemical structure is shown in FIG. 1.
- the derivatives herein provided are, in particular, isopropylamine analogues of sulfonated and phosphorylated mescaline derivatives.
- the present disclosure provides, in accordance with the teachings herein, in at least one embodiment, a chemical compound or salt thereof having chemical formula (I): wherein,
- Xi, X2, X3, X4, and Xs are independently or simultaneously H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi, X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two (or more) of Xi, X2, X3, X4, and X5 are H; and wherein
- W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3- 10-membered heterocyclic ring.
- the present disclosure provides sulfonated and phosphorylated chemical compounds which are derivatives of mescaline, notably isopropylamine derivatives having chemical formula (I), wherein 1 to 3 of Xi, X2, X3, X4, and Xs are a phosphate group or a sulfate group, and wherein additionally two (/.e., precisely two) of Xi, X2, X3, X4, and Xs are H.
- X2, X3 and X4 can be H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group or a glycosyloxy group, wherein 1 to 3 of X2, X3 and X4, can be a phosphate group or a sulfate group, bonded to carbon atoms C3, C4 and Cs, respectively.
- Xi and X5, in this example embodiment are hydrogen atoms.
- Xi, X3 and X4 can be H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X3 and X4, can be a phosphate group or a sulfate group, bonded to carbon atoms C2, C4 and Cs, respectively.
- X2 and Xs in this example embodiment are hydrogen atoms.
- Xi, X2 and X3 can be H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2 and X3, can be a phosphate group or a sulfate group, bonded to carbon atoms C2, C3 and C4, respectively.
- X4 and Xs in this example embodiment are hydrogen atoms.
- Xi, X3 and Xs can be H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X3 and Xs, can be a phosphate group or a sulfate group, bonded to carbon atoms C2, C4 and Cs, respectively.
- X2 and X4 in this example embodiment are hydrogen atoms.
- Xi, X2 and X4 can be H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2 and X4, can be a phosphate group or a sulfate group, bonded to carbon atoms C2, C3 and Cs, respectively.
- X3 and Xs in this example embodiment are hydrogen atoms.
- the positive charge on the nitrogen atom is counterbalanced with an anion (M _ ).
- M _ an anion
- the compounds of the present disclosure are zwitterionic, and a counterbalancing ion (M-) may not be required.
- FIG. 3K for example, shown therein is substantively the chemical compound of FIG. 3B wherein X3 has been selected to be a sulfate group.
- the chemical compound in FIG. 3K is a zwitterionic compound.
- Xi can be a sulfate group.
- X3 and Xs can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X2 and X4 in this example embodiment are hydrogen atoms.
- Xi can be a phosphate group.
- X3 and Xs can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X2 and X4 in this example embodiment are hydrogen atoms.
- X3 can be a sulfate group.
- Xi and Xs can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X3 can be a phosphate group.
- Xi and Xs can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xs can be a sulfate group.
- Xi and X3 can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xs can be a phosphate group.
- Xi and X3 can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi and X3 can each be a sulfate group.
- X5 can be selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi and X3 can each be a phosphate group.
- X5 can be selected from a hydrogen atom, an O- alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi and X5 can each be a sulfate group.
- X3 can be selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi and X5 can each be a sulfate group.
- X3 can be selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi can be a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X3 and X5 can each be a phosphate group.
- X3 can be a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X3 can be a phosphate group
- Xs can be a sulfate group
- Xi can be a hydrogen atom, an O- alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X3 can be a sulfate group, and Xs can be a phosphate group.
- Xi can be a hydrogen atom, an O- alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi can be a sulfate group
- Xs can be a phosphate group
- X3 can be a hydrogen atom, an O- alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi can be a phosphate group
- Xs can be a sulfate group
- X3 can be a hydrogen atom, an O- alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi, X3 and Xs can each be a phosphate group.
- Xi, X3 and Xs can each be a sulfate group.
- Xi can be a sulfate group
- X3 and Xs can each be a phosphate group.
- Xi and X4 can be a phosphate group and X3 can each be a sulfate group.
- Xi and X3 can be a sulfate group, and Xs can be a phosphate group.
- Xi and Xs can be a sulfate group and Xs can each be a phosphate group.
- the ionic phosphate and sulfate groups include positively charged cations. Whether such cations are included in the chemical compounds of the present disclosure can depend on, for example, whether the compounds possess other positively charged substituents. Thus, for example, as herein described, depending on the selection of substituents, the nitrogen atom (N) of the ethylamino chains, in some embodiments, be positively charged. Such positive charge may obviate the need for a cation to counterbalance ionic sulfate of phosphate groups.
- a covalent bond may be formed between a negatively charged oxygen atom of a phosphate or sulfate group and another atom, thus eliminating a negative charge.
- the phosphate group may in other embodiments be HPCU- or H2PO4, instead of PO4 2 ' , as shown in FIGS. 4B, 4D, 4F, 4H, 4J, 4L, 4P - 4Q, 4S - 4V, orthe sulfate group in other embodiments, may be HSO4, instead of SO4; as shown in FIGS. 4A, 4C, 4E, 4G, 41, 4K, 4N - 4P, and 4R - 4V.
- the phosphate or sulfate group can be an ionic phosphate or sulfate group and can form a phosphate or sulfate salt counterbalanced by a cation.
- the phosphate or sulfate group can be an ionic phosphate or ionic sulfate group and can form a phosphate or sulfate salt counterbalanced by a mono-valent, bi-valent, tri-valent, or tetra-valent cation.
- the phosphate group can be an ionic phosphate group and can form a phosphate salt with a mono-valent cation (Z + ), including any pharmaceutically acceptable monovalent cation, the salt having the formula: HPCU- Z + .
- the phosphate group can be an ionic phosphate group and can form a phosphate salt with a mono-valent cation (Z + ), the phosphate salt having the formula: (PO4 2 ')(Z + )2.
- the sulfate group can be an ionic sulfate group and can form a sulfate salt with a monovalent cation (Z + ), including any pharmaceutically acceptable monovalent cation, the sulfate salt having the formula: SO4' Z + .
- a monovalent cation can be selected from Na + , K + , NH4 + , tetra-n-butyl ammonium ([N(C4H9)4] + ), and triethyl ammonium (Et 3 NH 4 + ).
- the phosphate group can be an ionic phosphate group and can form a phosphate salt with a divalent cation (Z 2+ ), including any pharmaceutically acceptable divalent cation, the phosphate salt having the formula: PO4 2 ' Z 2+ .
- the phosphate group can be an ionic phosphate group and can form a phosphate salt with a divalent cation (Z 2+ ), the salt having the formula (HPO4')2 Z 2+ , wherein the second ionic phosphate group (/.e., the second of the two (HPCU groups) is a phosphate substituent of a second molecule of the compound having formula (I).
- a salt can for, example, have the chemical formula the formula (IV a ):
- the sulfate group can be an ionic sulfate group and can form a sulfate salt with a divalent cation (Z 2+ ), the salt having the formula (SO4')2 Z 2+ , wherein the second ionic sulfate group (SO4‘) (/.e., the second of the two (SO 4 -) groups) is a sulfate substituent of a second molecule of the compound having formula (I).
- SO4‘) /.e., the second of the two (SO 4 -) groups
- a salt can for, example, have the chemical formula the formula (V a ):
- a bivalent cation (Z 2+ ) can be selected from Mg 2+ and Ca 2+ .
- a trivalent cation for example, a trivalent metallic cation, such as Cr 3+ or Fe 3+ , or tetravalent cation (Z 4+ ), for example, a tetravalent metallic cation, such as Ti 4+ or Si 4+ may be used to counterbalance ionic phosphate or sulfate groups.
- FIGS. 4A - 4V Xi , X3 and X5 are bonded to carbon atoms C2, C4 and Ce, respectively. Furthermore, in these example compounds X2 and X4 are hydrogen atoms. In this respect, the example compounds shown in FIGS. 4A - 4V correspond with the compound shown in FIG. 3G. It is to be clearly understood, that, in this respect, FIGS. 4A - 4V represent example embodiments. Similarly, in further example embodiments, in accordance with the present disclosure, in each of the mescaline derivative compounds shown in FIGS.
- any one, any two, or any three of Xi, X2, X3, X4 and X5 can be a phosphate or sulfate group, wherein the Xi , X2, X3, X4, and Xs groups which are not a sulfate group or phosphate group, can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, and wherein two of Xi, X2, X3, X4, and Xs are a hydrogen atom.
- Xi, X2, X3, X4 and Xs can be a hydrogen atom, an O-alkyl group, an O-acyl group , a hydroxy group or a glycosyloxy group.
- O-alkyl groups include, without limitation, methoxy groups (-OCH3), ethanoxy groups (-OC2H5), propoxy groups (-OC3H7) and butanoxy groups (-OC4H9).
- O-acyl groups include, without limitation, acetoxy groups (-OCOCH3), propionyloxy groups (-OCOCH2CH3) and butyryloxy groups (-OCOCH2CH2CH3).
- glycosyl groups in accordance with the present disclosure, can be any glycosyl group, including a mono-, di-, tri- oligo- or a poly-saccharide group, bonded from the anomeric carbon, either in the pyranose or furanose form, either in the a- or the p-conformation.
- the glycosyl group may also be substituted with various groups.
- substitutions may include lower alkyl, lower alkoxy, acyl, carboxy, carboxyamino, amino, acetamido, halo, thio, nitro, keto, and phosphatyl groups.
- Such substitutions may be at one or more positions on the saccharide.
- the glycosyl group is a D-glucosyl group, D- fructosyl group, D-mannosyl group, D-ribosyl group, D-talosyl groups, D-lyxosyl group, D-allosyl group, D-altrosyl group, D-gulosyl group, D-isosyl group, D- quinovosyl group, D-maltosyl group, D-cellobiosyl group, D-lactosyl group, D- maltotiosyl group, D-glucuronic acid group, D-galactosyl group, D-fucosyl group, D-xylosyl group, D-arabinosyl group, or a D-rhamnosyl group.
- the glycosyl group is an L-glucosyl group, L- fructosyl group, L-mannosyl group, L-ribosyl group, L-talosyl groups, L-lyxosyl group, L-allosyl group, L-altrosyl group, L-gulosyl group, L-isosyl group, L- quinovosyl group, L-maltosyl group, L-cellobiosyl group, L-lactosyl group, L- maltotiosyl group, L-glucuromc acid group, L-galactosyl group, L-fucosyl group, L- xylosyl group, L-arabinosyl group, or a L-rhamnosyl group.
- X3 is a sulfate group, and Xi and Xs are each a hydroxy group.
- X3 is a phosphate group
- Xi and X5 are each a hydroxy group.
- X3 is a sulfate group
- Xi and Xs are each a methoxy group.
- X3 is a phosphate group
- Xi and X5 are each a methoxy group.
- X3 is a sulfate group, and Xi and Xs are each an acetoxy group.
- X3 is a phosphate group
- Xi and Xs are each an acetoxy group.
- X3 is a sulfate group
- Xi is an ethoxy group
- Xs is a hydroxy group
- X3 is a sulfate group
- Xi is an ethoxy group
- Xs is a hydroxy group
- X3 is a sulfate group
- Xi is a hydroxy group
- Xs is a propoxy group
- X3 is a phosphate group
- Xi is a hydroxy group
- Xs is a propoxy group
- X3 is a sulfate group, and Xi is an acetoxy group and Xs are each a propoxy group.
- X3 is a phosphate group, and Xi is an acetoxy group and Xs are each a propoxy group.
- FIGS. 5A- 5L Xi, X3 and Xs are bonded to carbon atoms C2, C4 and Ce, respectively. Furthermore, X2 and X4 are hydrogen atoms.
- the compounds shown in FIGS. 5A - 5L correspond with the compound shown in FIG. 3G.
- X3 is a sulfonyl or a phosphate group.
- the compounds shown in FIGS. 5A - 5L correspond with the compound shown in FIGS. 4C and 4D. It is to be clearly understood, that, in this respect, FIGS.
- any one, any two, or all three of Xi , X2, X3, X4 and X5 can be phosphate group or sulfate group, wherein Xi, X2, X3, X4 and X5 groups which are not a phosphate group or sulfate group, can be independently selected from a hydroxy group, an O-alkyl group, an O-acyl group, or a glycosyloxy group.
- any one of Xi, X3, and X5 can be independently selected from a hydroxy group, an O-alkyl group, an O-acyl group or a glycosyloxy group.
- W in the chemical compound having formula (I), in one embodiment, W can be -N(R4)(Rs), and R4 and Rs can be independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring.
- R4 and Rs are each a hydrogen atom.
- R4 and Rs are each an ethyl group or methyl group, respectively.
- R4 is a hydrogen atom and Rs is a methyl group.
- R4 and Rs are joined together and form a 6-membered heterocyclic ring (piperidine ring).
- W is N + (R6)(R7)(Rs)
- the compounds of the present disclosure may be zwitterionic, due to the presence of a negative charge on the phosphate or sulfate group (and the positive charge on the nitrogen atom).
- compounds, (III) and (IV) herein are zwitterionic compounds.
- W can be -N + (R6)(R7)(Rs), and Re, R7 and Rs can independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring.
- W when W is N + (Re)(R7)(Rs), the compound of Formula (I) includes a pharmaceutically acceptable anion.
- Re, R7 and Rs are each a hydrogen atom.
- Re and R7 are each a hydrogen atom, and Rs, is an ethyl group.
- Re and R7 are each an ethyl group, and Rs, is a hydrogen atom group.
- Re and R7 are joined together and form a 6-membered heterocyclic ring (piperidine ring), and Rs is a hydrogen atom.
- the positively charged nitrogen atom in the phenylisopropylamine chain is not counterbalanced by an exogenous cation. Instead, the positively charged nitrogen atom is counterbalanced by the ionic phosphate or sulfate groups these compounds possess.
- the negatively charged anions and positively charged cations (which may be denoted herein as M' (see: e.g., FIGS. 3H - 3J) and Z + (see: e.g., FIGS. 6G - 6H), respectively), can vary in different embodiments provided by the present disclosure.
- the corresponding counterion (cation or anion) is a pharmaceutically acceptable ion.
- Suitable cations include a potassium ion (K + ), sodium ion (Na + ), calcium ion (Ca 2+ ), magnesium ion (Mg 2+ ), ammonium ion (NH4 + ), tetra-n-butyl ammonium ion ([N(C4H9)4] + ), or triethyl ammonium ion (EtsNH4 + ), for example.
- any one, any two, or all three of Xi , X2, X3, X4 and X5 can be phosphate or sulfate groups, wherein the Xi, X2, X3, X4 and X5 groups which are not a sulfate group, can be independently selected from a hydroxy group, an O- alkyl group, an O-acyl group or a glycosyloxy group.
- any one of Xi, X3, and Xs can be independently selected from a hydroxy group, an O- alkyl group, an O-acyl group or a glycosyloxy group.
- W can be -N(R4)(RS), and the R4 and Rs groups are joined to form a heterocyclic ring, or W can be -N + (R6)(R7)(Rs), and two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring.
- the R4 and Rs groups or two of Re, R7 and Rs can be joined together to form a 4-10-membered heterocyclic ring (counting the nitrogen atom), wherein one or more carbons in the ring may be substituted with O, or NRe, wherein R9 is a hydrogen atom, or an alkyl, aryl, or acyl group.
- R4 and Rs are joined forming a 6-membered heterocyclic ring, and a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by an oxygen atom, forming a morpholinyl ring.
- R4 and Rs are joined forming a 6-membered heterocyclic ring, and a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by a nitrogen atom bonded to a hydrogen atom, forming a piperazine ring.
- R4 and Rs are joined forming a 6-membered heterocyclic ring, and a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by a nitrogen atom bonded to a methyl group, forming an N-methyl piperazine.
- the methyl group represents an example of an alkyl group.
- the nitrogen atom may be bonded to other alkyl groups.
- R4 and Rs are joined forming a 6-membered heterocyclic ring, and a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by a nitrogen atom bonded to an acetyl group, forming an N-acetyl piperazine.
- the acetyl group represents an example of an acyl group.
- the nitrogen atom may be bonded to other acyl groups.
- Re and R? are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring, and Rs is a hydrogen atom.
- Phospho compounds such as those shown in, for example, FIGS. 8L, 8N, 8P, 8R, and 8T) further include a negatively charged anion (Z + ) balancing the doubly negatively charged phospho group.
- Z + negatively charged anion
- sulfonyl compounds such as those shown in, for example, FIGS. 8K, 8M, 80, 8Q, and 8S
- the positively charged nitrogen atom is counterbalanced by the negatively charge sulfonyl group.
- Example embodiments in this respect are shown in FIGS. 8K - 8T.
- the positively charged cation can vary in different embodiments, and includes a potassium ion, a sodium ion, and an ammonium ion, for example.
- Re and R? are joined forming a 6-membered heterocyclic ring, and a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by an oxygen atom, forming a morpholinyl ring, and Rs is a hydrogen atom.
- Re and R? are joined forming a 6-membered heterocyclic ring, and a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by a nitrogen atom bonded to a hydrogen atom forming a piperazine ring, and Rs is a hydrogen atom.
- Re and R? are joined forming a 6-membered heterocyclic ring, and a carbon atom (together with its hydrogen atoms, relative to piperidine) is substituted by a nitrogen atom bonded to a methyl group, forming an N-methyl piperazine ring, and Rs is a hydrogen atom.
- the methyl group represents an example of an alkyl group.
- the nitrogen atom may be bonded to other alkyl groups.
- examples compounds in accordance with formula (I) are provided. These include compounds having the chemical formula: (III); (IV); and (V), as hereinafter depicted.
- the present disclosure provides a compound having chemical formula (III):
- the present disclosure provides a compound having chemical formula (V): wherein, Z +/2+ is a mono or divalent cation balancing the negatively charged sulfate group, forming a salt having the formula
- the present disclosure provides a chemical compound selected from (Vb); (V c ); (Vd); (V e ); (Vf); (V g ); and (Vh):
- the present disclosure relates to phosphorylated or sulfonated mescaline derivatives.
- the present disclosure provides, in particular, a chemical compound or salt thereof having formula (I): wherein,
- Xi , X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and Xs are a phosphate group or a sulfate group, and two of Xi , X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(RS) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring.
- one, two or three of Xi, X2, X3, X4, or Xs is phosphate group or a sulfate group.
- a glycosyloxy group e.g., phosphate group or
- R4, Rs, Re, R7, or Rs can be independently or simultaneously an alkyl group, (Ci-C2o)-alkyl group, (Ci-Cw)-alkyl group, (Ci-Ce)- alkyl group, or (Ci-C 3 )-alkyl group, -CH2-CH2-CH 3 (propyl); -CH2-CH 3 (ethyl); or - CH 3 (methyl)).
- R4 and Rs, or any two of Re, R7, and Rs can be a joined together to form a 3-10-membered heterocyclic ring, a 3-9-membered heterocyclic ring, or a 3-6-membered heterocyclic ring, or a 5-6-membered ring.
- the compound of formula (I) Xi or X 3 can be a phosphate group or sulfate group, and the compound of formula (I) can have a single a phosphate group or sulfate group,
- the compound of formula (I) can possess a single a phosphate group or sulfate group, and X2 orX 3 can be a phosphate group or sulfate group, and two of X 2 , X 3 , and X4 can be an O-alkyl group.
- the compound of formula (I) can possess a single a phosphate group or sulfate group, and X 2 can be a phosphate group or sulfate group, and X 3 and X4 can be an O-alkyl group.
- the compound of formula (I) can possess a phosphate group or sulfate group, and X 3 can be a phosphate group or sulfate group, and X 2 and X4 can be an O-alkyl group.
- the O-alkyl group can be independently or simultaneously selected from an O-(Ci-C6)-alkyl group, an O-(Ci-C 3 )-alkyl group, or a methoxy group (OCH 3 ).
- Example compounds in accordance with example embodiments, in his respect, include each of compounds (III); (IV); (V); (Vb); (V c ); (Vd); (V e ); (Vf); (V g ); and (V h ).
- the isopropylamine analogues of phosphorylated or sulfonated mescaline derivatives of the present disclosure may be used to prepare a pharmaceutical or recreational drug formulation.
- the present disclosure further provides in another aspect, pharmaceutical and recreational drug formulations comprising isopropylamine analogues of sulfonated or phosphorylated mescaline derivatives.
- the present disclosure provides in a further embodiment a pharmaceutical or recreational drug formulation comprising a chemical compound having chemical formula (I): wherein,
- Xi , X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two of Xi , X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(R 5 ) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10- membered heterocyclic ring, together with a diluent, carrier, or excipient.
- the pharmaceutical or recreational drug formulations may be prepared as liquids, tablets, capsules, microcapsules, nanocapsules, trans-dermal patches, gels, foams, oils, aerosols, nanoparticulates, powders, creams, emulsions, micellar systems, films, sprays, ovules, infusions, teas, decoctions, suppositories, etc. and include a pharmaceutically acceptable salt or solvate of the sulfonated and phosphorylated mescaline derivative compound together with an excipient.
- excipient as used herein means any ingredient other than the chemical compound of the disclosure.
- excipient may depend on factors such as the particular mode of administration, the effect of the excipient on solubility of the chemical compounds of the present disclosure and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in “Remington's Pharmaceutical Sciences”, 22nd Edition (Pharmaceutical Press and Philadelphia College of Pharmacy at the University of the Sciences, 2012).
- the pharmaceutical and drug formulations comprising the isopropylamine analogues of sulfonated or phosphorylated mescaline derivatives of the present disclosure may be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include both solid and liquid formulations.
- Solid formulations include tablets, capsules (containing particulates, liquids, microcapsules, or powders), lozenges (including liquid-filled lozenges), chews, multi- and nano-particulates, gels, solid solutions, liposomal preparations, microencapsulated preparations, creams, films, ovules, suppositories, and sprays.
- Liquid formulations include suspensions, solutions, syrups, and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. [00242] Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalhne cellulose, starch, and dibasic calcium phosphate di hydrate.
- lactose monohydrate, spray-dried monohydrate, anhydrous and the like
- mannitol xylitol
- dextrose sucrose
- sorbitol microcrystalhne cellulose
- starch and dibasic calcium phosphate di hydrate.
- Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80.
- surface active agents may comprise from 0.2% (w/w) to 5% (w/w) of the tablet.
- Tablets may further contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulfate.
- Lubricants generally comprise from 0.25% (w/w) to 10% (w/w), from 0.5% (w/w) to 3% (w/w) of the tablet.
- tablets may contain a disintegrant.
- disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkylsubstituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate.
- the disintegrant will comprise from 1 % (w/w) to 25% (w/w) or from 5% (w/w) to 20% (w/w) of the dosage form.
- auxiliary ingredients include antioxidants, colourants, flavouring agents, preservatives, and taste-masking agents.
- the chemical compound of the present disclosure may make up from 1 % (w/w) to 80 % (w/w) of the dosage form, more typically from 5% (w/w) to 60% (w/w) of the dosage form.
- Exemplary tablets contain up to about 80% (w/w) of the chemical compound, from about 10% (w/w) to about 90% (w/w) binder, from about 0% (w/w) to about 85% (w/w) diluent, from about 2% (w/w) to about 10% (w/w) disintegrant, and from about 0.25% (w/w) to about 10% (w/w) lubricant.
- the pharmaceutical and recreational drug formulations comprising the isopropylamine analogues of sulfonated or phosphorylated mescaline derivatives of the present disclosure may also be administered directly into the blood stream, into muscle, or into an internal organ.
- the pharmaceutical and recreational drug formulations can be administered parenterally (for example, by subcutaneous, intravenous, intraarterial, intrathecal, intraventricular, intracranial, intramuscular, or intraperitoneal injection).
- Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (in one embodiment, to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile water.
- excipients such as salts, carbohydrates and buffering agents (in one embodiment, to a pH of from 3 to 9)
- a suitable vehicle such as sterile water.
- Formulations comprising the isopropylamine analogues of sulfonated or phosphorylated mescaline derivatives of the present disclosure for parenteral administration may be formulated to be immediate and/or modified release.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- the chemical compounds of the disclosure may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound.
- Examples of such formulations include drug-coated stents and poly(dl- lactic-coglycolic)acid (PGLA) microspheres.
- the pharmaceutical or recreational drug formulations of the present disclosure also may be administered topically to the skin or mucosa, i.e., dermally or transdermally.
- Example pharmaceutical and recreational drug formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, cosmetics, oils, eye drops, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used.
- Example carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
- Penetration enhancers may be incorporate (see: for example, Finnin, B. and Morgan, T.M., 1999 J. Pharm. Sci, 88 (10), 955-958).
- Topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g., PowderjectTM, BiojectTM, etc.) injection.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid pharmaceutical compositions can contain suitable pharmaceutically acceptable excipients.
- the pharmaceutical compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Pharmaceutical compositions in pharmaceutically acceptable solvents can be nebulized by use of inert gases. Nebulized solutions can be inhaled directly from the nebulizing device, or the nebulizing device can be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder pharmaceutical compositions can be administered, e.g., orally or nasally, from devices that deliver the formulation in an appropriate manner.
- the isopropylamine analogues of sulfonated or phosphorylated mescaline compounds of present disclosure are used as a recreational drug
- the compounds may be included in compositions such as a food or food product, a beverage, a food seasoning, a personal care product, such as a cosmetic, perfume or bath oil, or oils (both for topical administration as massage oil, or to be burned or aerosolized).
- a personal care product such as a cosmetic, perfume or bath oil, or oils (both for topical administration as massage oil, or to be burned or aerosolized).
- the chemical compounds of the present disclosure may also be included in a “vape” product, which may also include other drugs, such as nicotine, and flavorings.
- the compounds may be metabolized by the subject, and converted into other chemical entities.
- the compounds may be hydrolyzed, and phosphate or sulfate groups may be removed from the compounds, for example, by an endogenously present phosphatase or sulfatase.
- the pharmaceutical formulations comprising the chemical compounds of the present disclosure may be used to treat a subject, and in particular to treat a psychiatric disorder in a subject.
- the present disclosure includes in a further embodiment, a method for treating a brain neurological disorder, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising a chemical compound or salt thereof having chemical formula (I): wherein,
- Xi, X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and Xs are a phosphate group or a sulfate group, and two of Xi, X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(RS) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3- 10-membered heterocyclic ring, together with a diluent, carrier, or excipient.
- the phosphorylated and sulfonated mescaline derivative compounds may be used as a pharmaceutical or recreational drug. Accordingly, in another aspect the present disclosure provides, in at least one embodiment, a use of a chemical compound or salt thereof having a chemical formula (I): wherein,
- Xi, X2, X3, X4, and Xs are H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi , X2, X3, X4, and Xs are a phosphate group or a sulfate group, and two of Xi, X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(RS) or -N + (R6)(R7)(RS); (i) R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3- 10-membered heterocyclic ring, as a recreational drug or pharmaceutical drug, including as a pharmaceutical drug to treat a brain neurological disorder.
- Brain neurological disorders include psychiatric disorders that may be treated for example, neurodevelopmental disorders such as intellectual disability, global development delay, communication disorders, autism spectrum disorder, and attention-deficit hyperactivity disorder (ADHD); bipolar and related disorders, such as mania, and depressive episodes; anxiety disorder, such as generalized anxiety disorder (GAD), agoraphobia, social anxiety disorder, specific phobias (natural events, medical, animal, situational, for example), panic disorder, and separation anxiety disorder; stress disorders, such as acute stress disorder, adjustment disorders, post-traumatic stress disorder (PTSD), and reactive attachment disorder; dissociative disorders, such as dissociative amnesia, dissociative identity disorder, and depersonalization/derealization disorder; somatoform disorders, such as somatic symptom disorders, illness anxiety disorder, conversion disorder, and factitious disorder; eating disorders, such as anorexia nervosa, bulimia nervosa, rumination disorder, pica, and binge-eating disorder; sleep disorders, such as narcolepsy
- Brain neurological disorders further include headache disorders, including migraines, including, for example, aural migraine
- the compounds of the present disclosure may be used to be contacted with a receptor to thereby modulate the receptor.
- Such contacting includes bringing a compound of the present disclosure and receptor together under in vitro conditions, for example, by introducing the compounds in a sample containing a receptor, for example, a sample containing purified receptors, or a sample containing cells comprising receptors.
- In vitro conditions further include the conditions described in Example 1 hereof.
- Contacting further includes bringing a compound of the present disclosure and receptor together under in vivo conditions.
- Such in vivo conditions include the administration to an animal or human subject, for example, of a pharmaceutically effective amount of the compound of the present disclosure, when the compound Is formulated together with a pharmaceutically active carrier, diluent, or excipient, as hereinbefore described, to thereby treat the subject.
- the compound Upon having contacted the receptor, the compound may activate the receptor or inhibit the receptor.
- the reaction conditions can be in vivo reaction conditions, and the in vivo reaction conditions comprise administering an effective amount of the chemical compound to a human or animal subject possessing a 5- HT2A receptor and a 5-HTIA receptor, wherein the 5-HT2A receptor is modulated and the 5-HTIA receptor is not modulated.
- the reaction conditions can be in vivo reaction conditions, and the in vivo reaction conditions comprise administering an effective amount of the chemical compound to a human or animal subject possessing a 5-HT2A receptor and a 5-HTIA receptor, wherein both the 5-HT2A and the 5-HTIA receptor are modulated.
- receptors with which the compounds of the present disclosure may be contacted include, the HT2A or HTi A receptors.
- the mescaline derivatives of the present disclosure may bind to a variety of receptors, 5-HT2A and 5-HTIA receptors are considered to be particularly relevant because in vitro agonism of mescaline, and certain mescaline derivatives at these receptors has been correlated with key effects of drug action(s).
- the mescaline derivative and therapeutic agent 3,4-methylenedioxy- methamphetamine (MDMA) is a 5-HT2A receptor agonist (Simmler et al., 2013, British J. Pharmacol. 168: 458), and this effect is thought to be responsible for the MDMA-induced mesolimbic dopamine release (Dunlap et al., 2018, ACS Chem. Neurosci. 9: 2408).
- MDMA is also a 5-HTIA receptor agonist (Simmler et al., 2013, British J. Pharmacol. 168: 458; mescaline, Rickli et al., 2016, Eur. Neuropharm. 26: 1327) and even micromolar in vitro Kivalues for MDMA at 5-HTiA appear to be physiologically relevant.
- MDMA administration results in a postsynaptic upregulation of the 5-HTIA receptor in the cortex and hypothalamus that is noticeable 1 week after acute administration (Inserra et al., 2020, Pharmacol. Rev. 73: 202).
- MDMA is a therapeutic agent used in U.S. -based clinical trials for the treatment of post-traumatic stress disorder (PTSD), anxiety and other neuropathologies (Dunlap et al., 2018, ACS Chem. Neurosci .9: 2408).
- mescaline and certain mescaline derivatives 4-Bromo-2,5-dimethoxyphenethylamine (2C-B), escahne, and proscahne.
- Mescaline s effects are attributed in large part to its action as a 5-HT2A serotonin receptor agonist, although mescaline binds in a similar concentration range to 5-HT IA prompting recent consideration of 5-HT IA as an additional key target (Cassels and Saez-Briones, 2018, ACS Chem. Neurosci. 9: 2448).
- assays for determining receptor binding of a given compound include ligand competition assays with an established radiolabeled ligand, resulting in a Ki value. Additional assays may be performed wherein positive and negative controls with pre-determined Ki values are titrated to cell cultures with engineered ‘receptor response systems.’
- condition that may be treated in accordance herewith can be any receptor mediated disorder, including, for example, an HT2A receptor-mediated disorder or HTIA receptor-mediated disorder.
- HT2A receptor-mediated disorder or HTIA receptor-mediated disorder.
- disorders include, anxiety, depression, schizophrenia, and PTSD, for example.
- the compound having formula (I) upon administration can interact with a 5-HTIA receptor and a 5-HT2A receptor in the subject to thereby modulate both the 5-HTIA receptor and the 5-HT2A receptor and exert a pharmacological effect.
- the compound having formula (I) upon administration can interact with a 5-HT2A receptor in the subject to thereby modulate the 5-HT2A receptor without modulating the 5-HTIA receptor and exert a pharmacological effect.
- the compound upon having contacted a receptor, may modulate the receptor. However, at the same time other receptors may not be modulated. For example, a compound may activate or inhibit a first receptor, however the compound may at the same time not modulate a second receptor, or upon having contacted a first receptor and a second receptor, the compound may modulate the first receptor, however the compound may at the same time not modulate the second receptor.
- the isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives of the present disclosure may be prepared in any suitable manner, including by any organic chemical synthesis methods, biosynthetic methods, or a combination thereof.
- One suitable method of to making the isopropylamine analogues of sulfonated and phosphorylated mescaline derivatives of the present disclosure initially involves selecting and obtaining or preparing a precursor compound of an isopropylamine analogue of a phosphorylated or sulfonated mescaline derivative compound and a phosphor-oxidous or a sulfur-oxidous compound and reacting the precursor compound and the phosphor-oxidous compound or sulfur-oxidous compound to obtain an isopropylamine analogue of a phosphorylated and sulfated mescaline derivative of the present disclosure.
- Suitable precursor compounds include compounds comprising the prototype structure shown in FIG. 2, including, for example, in an embodiment, a chemical compound having the formula (II): wherein,
- Xi , X2, X 3 , X 4 , and Xs are H, a reactive group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi, X2, X 3 , X 4 , and Xs are a reactive group, and two of Xi, X2, X 3 , X 4 , and Xs are H; and wherein
- W is -CH2CH(CH 3 )N(R 4 )(R5) or -CH 2 CH(CH 3 )N + (R6)(R7)(R8);
- R 4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R 4 , and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R? and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring;
- the reactive group can be a hydroxy group.
- FIGS. 10A, 10B, 10C, 11, and 12 Examples of suitable chemical reactions that may be performed in accordance herewith are depicted in FIGS. 10A, 10B, 10C, 11, and 12, and are hereinafter further detailed, including in the Example section.
- the precursor compound of the isopropylamine analogue of a sulfonated or phosphorylated mescaline derivative may be provided in a more or less chemically pure form, for example, in the form of a hydroxy-containing mescaline derivative preparation having a purity of at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least 99.9%.
- the precursor compound of the sulfonated or phosphorylated mescaline derivative mescaline derivative may be chemically synthesized or obtained from a fine chemical manufacturer.
- any phosphor-oxidous compounds and sulfur-oxidous compounds may be selected, obtained, or prepared, for example, using a suitably protected phenolic derivative which is then subjected to either a phosphorylation or sulfation on the available hydroxyl group(s) on the benzene ring.
- Suitable sulfur-oxidous compounds that may be used in this respect include, for example, pyridinium sulfur trioxide and tetrabutylammonium hydrogen sulfate, and suitable phosphorus-oxidous compounds that may be used in this respect include, for example, tetra-O-benzyl pyrophosphate, and dibenzyl chlorophosphite.
- a precursor compound of an isopropylamine analogues of sulfonated or phosphorylated mescaline derivative is provided, and the precursor compound of the isopropylamine analogue of a sulfonated or phosphorylated mescaline derivative and sulfur-oxidous or phosphor-oxidous compound are contacted to react in a chemical reaction resulting in the formation of an isopropylamine analogue of a phosphorylated or sulfonated mescaline derivative compound.
- the phosphor-oxidous compound or sulfur-oxidous compound may be provided in a more or less chemically pure form, for example, in the form of a phosphate or sulfate compound preparation having a purity of at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least 99.9%.
- the phosphor-oxidous compound or sulfur-oxidous compound may be chemically synthesized or obtained from a fine chemical manufacturer.
- one, two or three of Xi, X2, X3, X4, and X5 in compound (II) can be reactive hydroxy groups, O-alkyl groups, or hydrogen atoms.
- one, two or three of X2, X3 and X4 in compound (II) can be a reactive hydroxy group, wherein when (i) one of X2, X3, and X4, is an hydroxy group, the other two of X2, X3 and X4 are independently selected from a glycosyloxy group, an O-alkyl group, an O-acyl group, and each of Xi and X5 are a hydrogen atom, (ii) when two of X2, X3, and X4, are an hydroxy group, the other one of X2, X3 and X4 is selected from a glycosyloxy group an O-alkyl group, an O- acyl group, and each of Xi, and Xs are a hydrogen atom, and (iii) when three of X2, X3, and X4, are an hydroxy group, each of Xi, and Xs are a hydrogen atom.
- one, two or three of Xi, X3 and X4 in compound (II) can be a reactive hydroxy group, wherein when (i) one of Xi, X3, and X4, is an hydroxy group, the other two of Xi, X3 and X4 are independently selected from a glycosyloxy group, an O-alkyl group, an O-acyl group, and each of X2 and Xs are a hydrogen atom, (ii) when two of Xi, X3, and X4, are an hydroxy group, the other one of Xi, X3 and X4 is selected from a glycosyloxy group an O-alkyl group, an O- acyl group, and each of X2, and Xs are a hydrogen atom, and (iii) when three of Xi, X3, and X4, are an hydroxy group, each of X2, and Xs are a hydrogen atom.
- one, two or three of Xi, X2 and X3 in compound (II) can be a reactive hydroxy group, wherein when (i) one of Xi, X2, and X3, is an hydroxy group, the other two of Xi, X2 and X3 are independently selected from a glycosyloxy group, an O-alkyl group, an O-acyl group, and each of X4 and Xs are a hydrogen atom, (ii) when two of Xi, X2, and X3, are an hydroxy group, the other one of Xi, X2 and X3 is selected from a glycosyloxy group an O-alkyl group, an O- acyl group, and each of X4, and Xs are a hydrogen atom, and (iii) when three of Xi, X2, and X3, are an hydroxy group, each of X4, and Xs are a hydrogen atom.
- one, two or three of Xi, X3 and Xs in compound (II) can be a reactive hydroxy group, wherein when (i) one of Xi, X3, and Xs, is an hydroxy group, the other two of Xi, X3 and Xs are independently selected from a glycosyloxy group, an O-alkyl group, an O-acyl group, and each of Xi and Xs are a hydrogen atom, (ii) when two of Xi, X3, and Xs, are an hydroxy group, the other one of Xi, X3 and X5 is selected from a glycosyloxy group an O-alkyl group, an O- acyl group, and each of X2, and X4 are a hydrogen atom, and (iii) when three of Xi, X3, and Xs, are an hydroxy group, each of X2, and X4 are a hydrogen atom.
- one, two or three of Xi, X2 and X4 in compound (II) can be a reactive hydroxy group, wherein when (i) one of Xi, X2, and X4, is an hydroxy group, the other two of Xi, X2 and X4 are independently selected from a glycosyloxy group, an O-alkyl group, an O-acyl group, and each of X3 and X5 are a hydrogen atom, (ii) when two of Xi, X2, and X4, are an hydroxy group, the other one of Xi, X2 and X4 is selected from a glycosyloxy group an O-alkyl group, an O- acyl group, and each of X3, and X5 are a hydrogen atom, and (iii) when three of Xi, X2, and X4, are an hydroxy group, each of X3, and X5 are a hydrogen atom.
- R4 and Rs can independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring.
- R4 and Rs can each be a hydrogen atom (Wthus being NH2), or R4 and Rs can each be an oxygen atom (W thus being NO2), or R4 and Rs can each be a nitrogen atom ((W thus being N3).
- Re, R7 and Rs can independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring.
- the reactive group can be a hydroxy group and the sulfur-oxidous compound can be a pyridinium sulfur trioxide.
- the reactive group can be a hydroxy group and the phosphor-oxidous compound can be tetra-O-benzyl pyrophosphate.
- the reactive group can be a hydroxy group and the sulfur-oxidous compound can be a pyridinium sulfur trioxide, and R4 and Rs in the chemical compound having formula (II) can both be H, O, or N.
- the reactive group can be a hydroxy group and the phosphor-oxidous compound can be tetra-O-benzyl pyrophosphate, and R4 and Rs in the chemical compound having formula (II) can both be H, O, or N.
- R4 or Rs, or any two of Re, R7, or Rs groups can be joined together to form a 4-10-membered heterocyclic ring, wherein one or more carbons in the ring may be substituted with O, or NR9, wherein R9 is a hydrogen atom, or an alkyl, aryl, or acyl group.
- FIGS. 9A - 9G shown therein are example hydroxy-containing mescaline derivatives.
- Xi can be a reactive hydroxy group.
- R2 and R3 can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X3 can be a reactive hydroxy group.
- R1 and R3 can be independently selected from a hydrogen atom, an O-alkyl group, an acyl group, a hydroxy group, or a glycosyloxy group.
- Xs can be a reactive hydroxy group.
- R1 and R2 can be independently selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi and X3 can each be a reactive hydroxy group.
- R3 can be selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi and Xs can each be a reactive hydroxy group.
- R1 can be selected from a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- X3 and Xs can each be a hydroxy group.
- R1 can be a hydrogen atom, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group.
- Xi, X3 and Xs can each be a reactive hydroxy group.
- FIGS. 9A - 9G Xi, X3 and Xs, in the chemical compound having chemical formula (II), are bonded to carbon atoms C2, C4 and Ce, respectively. Furthermore, X2 and X4 are hydrogen atoms.
- the compounds shown in FIGS. 9A - 9G can be understood to correspond with the compound shown in FIG. 3G. It is further noted that the hydroxy-containing derivates shown in FIGS. 9A - 9G may be used to make the isopropylamine analogues of phosphorylated and sulfonate mescaline derivatives shown in FIGS. 4A - 4V, respectively.
- FIGS. 9A - 9G represent example embodiments.
- mescaline derivative compounds shown in FIGS. 3A - 3F, and 3H - 3I may be selected, wherein any one, any two, or all three of Xi, X3 and X5 can be reactive hydroxy groups, wherein the Xi, X3 and X5 groups which are not a hydroxy group, can be independently selected from a hydrogen atom, an alkyl group, or an acyl group. Any thus selected hydroxy-containing mescaline derivatives may all be used to make isopropylamine analogues of phosphorylated and sulfonated mescaline derivatives in accordance with the present disclosure.
- FIG. 10A shown therein is an example of chemical synthesis of monosulfate- or monophosphate-functionalized isopropylamine mescaline derivatives using 2-bromo-5-tert-butyldiphenylsilyloxy-1 ,3- dimethoxybenzene (10A-1) as a starting material.
- a treatment with n-butyllithium can regio-selectively introduce a substituted phenyllithium intermediate via lithiumhalogen exchange.
- the obtained reactive organolithium can then be quenched with 1 ,2-epoxypropane to afford the corresponding 5-tert-butyldiphenylsilyloxy-2- (2-hydroxypropyl)-1 ,3-dimethoxybenzene (10A-2).
- the alcohol can then be activated via a O-mesylation with methansulfonyl chloride in the presence of pyridine to afford the corresponding mesylate (10A-3) which can be subsequently displaced with an azide, to provide the desired 2-(2-azidopropyl)-5-tert- butyldiphenylsilyloxy-1 ,3-dimethoxybenzene (10A-4).
- the O-tert-butyldiphenylsilyl protecting group of compound (10A-4) can then be removed by a treatment with tetra-n-butylammonium fluoride to provide the corresponding phenol derivative (10A-5).
- an O-monosulfation can be carried out by treating with sulfur trioxide - pyridine complex to provide an intermediate whose counter cation can be exchanged with sodium using a resin such as Amberlite IR-120 (Na + ), and finally the azide functional group can be reduced via a hydrogenation to provide the desired monosulfate-functionalized isopropylamine mescaline derivative (10A-6).
- a monophosphorylation can be carried out via the reaction with tetra-O-benzyl pyrophosphate to install a O,O-dibenzylphosphate group (10A-7).
- the O-benzyl protecting groups and the side chain azido functionality can be further reduced via a catalytic hydrogenation.
- a resin such as Amberlite IR-120 (Na + )
- the desired O-phosphate-functionalized isopropylamine mescaline derivative (10A-8) can be obtained.
- FIG. 10B shown therein is an example of chemical synthesis of monosulfate- or monophosphate-functionalized N,N-disubstituted isopropylamine mescaline derivatives using 2-bromo-5-benzyloxy-1 ,3- dimethoxybenzene (10B-1 ) as a starting material.
- a treatment with n-butyllithium can regio-selectively introduce a substituted phenyllithium intermediate via lithiumhalogen exchange.
- the obtained reactive organolithium can then be quenched with 1 ,2-expoxypropane to provide the corresponding 5-benzyloxy-2-(2- hydroxypropyl)-1 ,3-dimethoxybenzene (10B-2).
- the alcohol can then be activated via an O-mesylation with methansulfonyl chloride in the presence of pyridine to provide the corresponding mesylate (10B-3) which can be subsequently displaced with a substituted amine such as N,N-dimethylamine, to provide the desired 2-(2- N,N-dimethylaminopropyl)-5-benzyloxy-1 ,3-dimethoxybenzene (10B-4).
- the O- benzyl protecting group of compound (10B-4) can then be removed by a catalytic hydrogenation to afford the corresponding phenol derivative (10B-5).
- an O-monosulfation can be carried out by treating with sulfur trioxide - pyridine complex to provide an intermediate whose counter cation can be exchanged with sodium using a resin such as Amberlite IR- 120 (Na + ) to provide the desired monosulfate-functionalized N,N-dimethyl isopropylamine mescaline derivative (10B-6).
- a resin such as Amberlite IR- 120 (Na + ) to provide the desired monosulfate-functionalized N,N-dimethyl isopropylamine mescaline derivative (10B-6).
- a monophosphorylation can be carried out via the reaction with tetra-O-benzyl pyrophosphate to install a O,O-dibenzylphosphate group (10B-7).
- the O-benzyl protecting groups and the side chain azido functionality can be further reduced via a catalytic hydrogenation.
- a catalytic hydrogenation After subjecting the intermediate to a cation exchange with a resin such as Amberlite IR-120 (Na + ), the desired O-phosphate-functionalized N,N-dimethyl isopropylamine mescaline derivative (10B-8) can be obtained.
- FIG. 10C shown therein is an example of chemical synthesis of disulfate- or diphosphate-functionalized isopropylamine mescaline derivatives using 2,4,6-hihydroxybenzaldehyde (10C-1) as a starting material.
- a treatment with two equivalents of tert-butyldiphenylsilyl chloride can regio- selectively introduce two O-silyl protecting groups to provide the corresponding
- the remaining hydroxyl group can be alkylated such as reacting with iodoethane in the presence of potassium carbonate.
- the obtained fully protected benzaldehyde (10C-3) can then be subjected to a condensation with nitroethane to provide a E,Z-mixture of nitroalkene products (10C-4).
- the conjugated nitroalkene functionality can then be reduced with sodium borohydride to provide the corresponding 2-(2-nitropropyl)-
- a O,O-disulfonation can be carried out by treating with sulfur trioxide - pyridine complex to provide an intermediate whose counter cation can be exchange with sodium using a resin such as Amberlite IR-120 (Na + ), and finally the nitro functional group can be reduced via a hydrogenation to afford the desired disulfate-functionalized isopropylamine mescaline derivative (10C-7).
- a O,O-diphosphorylation can also be carried out via the reaction with an excess of tetra-O-benzyl pyrophosphate to install two O,O-dibenzylphosphate groups (10C-8). All of the O-benzyl protecting groups and the side chain nitro functionality can be further reduced via a catalytic hydrogenation.
- a resin such as Amberlite IR-120 (Na + )
- the desired diphosphate- functionalized isopropylamine mescaline derivative (10C-9) can be obtained.
- Xi, X2, X3, X4, and Xs are independently or simultaneously H, a phosphate group, a sulfate group, an O-alkyl group, an O-acyl group, a hydroxy group, or a glycosyloxy group, wherein 1 to 3 of Xi, X2, X3, X4, and X5 are a phosphate group or a sulfate group, and two (or more) of Xi, X2, X3, X4, and Xs are H; and wherein
- W is -N(R 4 )(RS) or -N + (R6)(R7)(R 8 );
- R4 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or R4, and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3-10-membered heterocyclic ring; or
- Re, R7 and Rs are independently or simultaneously H, an alkyl group, or an acyl group, or any two of Re, R7 and Rs are joined together, along with the nitrogen atom to which they are attached, to form a 3- 10-membered heterocyclic ring, wherein the method involves performing at least one of the chemical synthesis reactions depicted in FIGS. 10A, 10B, 10C, 11, or 12.
- the compound having formula (I) can be a compound having chemical formula (III): and the least one chemical synthesis reaction is selected from chemical reaction (d); (c) and (d); (b), (c), and (d); and (a), (b), (c), and (d) depicted in FIG. 11.
- the reactions can be conducted under the conditions identified in FIG. 11 , and as described in further detail in Example 1 , however, as will be readily understood to those of skill in the art, the reaction conditions may be modified, to establish other conditions sufficient to conduct the noted reactions and obtain the desired product or intermediate product.
- temperatures, reaction times, and other conditions may be varied, for example, by evaluating the obtained compounds under a series of different conditions (e.g., different temperatures, reaction times etc.), and selecting a preferred condition.
- the compound having formula (I) can be a compound having chemical formula (IV): and the least one chemical synthesis reaction is selected from chemical reaction f); (e) and (f); (d), (e), and (f); (c), (d), (e), and (f); (b), (c), (d) (e), and (f); and (a), (b), (c), (d) (e), and (f) depicted in FIG. 12.
- the reactions can be conducted under the conditions identified in FIG. 12, and as described in further detail in Example 2, however, as will be readily understood to those of skill in the art, the reaction conditions may be modified, to establish other conditions sufficient to conduct the noted reactions and obtain the desired product or intermediate product.
- temperatures, reaction times, and other conditions may be varied, for example, by evaluating the obtained compounds under a series of different conditions (e.g., different temperatures, reaction times etc.), and selecting a preferred condition.
- the compound having formula (I) can be a compound having chemical formula (V c ):
- the least one chemical synthesis reaction is selected from chemical reaction (d); (c) and (d); (b), (c), and (d); and (a), (b), (c), and (d) depicted in FIG. 12.
- the reactions can be conducted under the conditions identified in FIG. 12, and as described in further detail in Example 3, however, as will be readily understood to those of skill in the art, the reaction conditions may be modified, to establish other conditions sufficient to conduct the noted reactions and obtain the desired product or intermediate product.
- temperatures, reaction times, and other conditions may be varied, for example, by evaluating the obtained compounds under a series of different conditions (e.g., different temperatures, reaction times etc.), and selecting a preferred condition.
- the reactions may be conducted in any suitable reaction vessel (e.g., a tube, bottle).
- suitable solvents that may be used are polar solvents such as, for example, dichloromethane, dichloroethane, toluene, and so-called participating solvents such as acetonitrile and diethyl ether.
- Further suitable solvents that may be used are for example, water, alcohol (such as methanol, ethanol, tetrahydrofuran (THF), dichloromethane, acetone, N,N- dimethylformamide (DMF), dimethylsulfoxide (DMSO), or a combination of solvents.
- Suitable temperatures may range from, for example, e.g., from about - 78 °C to about 100 °C.
- catalysts also known as promoters, may be included in the reaction such as iodonium dicollidine perchlorate (IDCP), any silver or mercury salts, trimethylsilyl trifluoromethanesulfonate (TMS-triflate, TMSOTf), or trifluoronmethanesulfonic acid (triflic acid, TfOH), N-iodosuccinimide, methyl triflate.
- IDCP iodonium dicollidine perchlorate
- TMSOTf trimethylsilyl trifluoromethanesulfonate
- TfOH trifluoronmethanesulfonic acid
- reaction times may be varied.
- reaction conditions may be optimized, for example, by preparing several phosphate or sulfate containing compound preparations and hydroxy-containing mescaline derivative preparations and reacting these in different reaction vessels under different reaction conditions, for example, different temperatures, using different solvents etc., evaluating the obtained phosphorylated or sulfonated mescaline derivative reaction product, adjusting reaction conditions, and selecting a desired reaction condition.
- reaction conditions for performing sulfonation and phosphorylation reactions may be found in e.g., U. Pradere, et al., Chem. Rev. 2014, 114, 9154-9218; W. Kozak, et a!., Asian J. Org. Chem. 2018, 7,314 -323.
- PrestoBlue assays were first performed.
- the PrestoBlue assay measures cell viable activity based on the metabolic reduction of the redox indicator resazurin and is a preferred method for routine cell viability assays (Terrasso et al., 2017, J Pharmacol. Toxicol. Methods 83: 72).
- Results of these assays were conducted using both control ligands (e.g., 2C-B (4-bromo-2,5-dimethoxyphenethylamine), MDMA, mescaline, etc.) and novel derivative, in part as a pre-screen for any remarkable toxic effects on cell cultures up to concentrations of 1 mM.
- HepG2 is a human hepatoma that is most commonly used in drug metabolism and hepatotoxicity studies (Donato et al., 2015, Methods Mol Biol 1250: 77).
- HepG2 cells were cultured using standard procedures using the manufacture’s protocols (ATCC, HB-8065). Briefly, cells were cultured in Eagle’s minimum essential medium supplemented with 10% fetal bovine serum and grown at 37°C in the presence of 5% CO2. To test the various compounds with the cell line, cells were seeded in a clear 96-well culture plate at 20,000 cells per well. After allowing cells to attach and grow for 24 hours, compounds were added at 1 mM, 10 mM, 100 mM, and 1 mM. Methanol was used as vehicle, at concentrations 0.001 , 0.01 , 0.1 , and 1 %.
- Triton X-100 concentrations used were 0.0001 , 0.001 , 0.01 and 0.1 %.
- DMSO was added percent-wise up to 1 % (v/v) as a negative control.
- Cells were incubated with compounds for 48 hours before assessing cell viability with the PrestoBlue assay following the manufacture’s protocol (ThermoFisher Scientific, P50200).
- PrestoBlue reagent was added to cells and allowed to incubate for 1 hour before reading. Absorbance readings were performed at 570 nm with the reference at 600 nm on a SpectraMax iD3 plate reader. Non-treated cells were assigned 100% viability.
- 13 (i), and 13 (ii) show results for phenylalkylamine compounds 2C-B (4-bromo-2,5-dimethoxyphenethylamine) (Panel A), MDMA (Panel B), mescaline (Panel C), non-toxic DMSO (Panel D), and the toxic control compound Triton X100 (Panel E).
- Data acquired for the derivative having chemical formula (III) is displayed as “(III)” on the x-axis in Panel F.
- SPA beads RPNQ0011
- radiolabeled 8-hydroxy-DPAT [propyl-2,3- ring-1 ,2,3- 3 H] (NET929250UC)
- isoplate-96 microplate 6005040
- Radioactive binding assays were carried out using the Scintillation Proximity Assay (SPA).
- mixtures of 10 pg of membrane containing HTIA receptor was pre-coupled to 1 mg of SPA beads at room temperature in a tube rotator for 1 hour in binding buffer (50 mM Tris-HCI pH 7.4, 10 mM MgSO4, 0.5 mM EDTA, 3.7% glycerol, 1 mM ascorbic acid, 10 pM pargyline HCI).
- binding buffer 50 mM Tris-HCI pH 7.4, 10 mM MgSO4, 0.5 mM EDTA, 3.7% glycerol, 1 mM ascorbic acid, 10 pM pargyline HCI.
- the beads and membrane were aliquoted in an isoplate-96 microplate with increasing amounts of 8-hydroxy-DPAT [propyl-2,3- ring-1 ,2,3- 3 H] (0.1525 nM to 5 nM) and incubated for two hours at room temperature in the dark with shaking.
- Ki values were calculated from the competition displacement data using the competitive binding analysis from GraphPad PRISM software. 2C-B, MDMA and mescaline were used as positive controls since they are phenylalkylamine-type molecules with relatively strong (2C- B; Rickli et al., 2015, Neuropharmacology 99: 546) or more moderate (MDMA, Simmler et a/., 2013, British J. Pharmacol.
- FIGS. 13B, 13C, and 13D show the competition binding curves for 2C-B, MDMA and mescaline, respectively, as positive controls (binding).
- FIG. 13E and 13F show the competition binding curves for escaline and proscaline, respectively, for comparative purposes.
- FIG. 13G shows the competition binding curve for tryptophan as a negative control (no significant binding, as indicated by a Ki value >1000 pM).
- the competition binding curve for compound with formula (III), designated “III” in FIG. H reveals no significant binding to the 5-HTIA, as evidenced by a Ki value > 1000 pM.
- Assays for determining receptor binding of a given compound include ligand competition assays with an established radiolabeled ligand, resulting in a value. Additional assays may be performed wherein positive and negative controls with pre-determined values are titrated to cell cultures with engineered ‘receptor response systems.’
- Results of these cellular assays can provide certain information regarding the overall strength of receptor activation, although negative results in these artificial systems do not necessarily correlate with in vivo impact.
- a variety of positive controls MDMA, 2C-B, mescaline, escaline, proscahne
- mescaline, escaline, proscahne with established receptor binding and known in vivo efficacy profiles are included in cellular assays.
- [ 3 H]ketanserin is a well-established antagonist used routinely in competition assays to evaluate competitive activity of novel drug candidates at the 5-HT2A receptor (Maguire et a/., 2012, Methods Mol Biol 897: 31).
- competition assays using [ 3 H]ketanserin were employed as follows. SPA beads (RPNQ0010), [ 3 H]ketanserin (NET1233025UC), membranes containing 5-HT2A (ES-313- M400UA), and isoplate-96 microplate (6005040) were all purchased from PerkinElmer.
- Radioactive binding assays were carried out using Scintillation Proximity Assay (SPA).
- SPA Scintillation Proximity Assay
- mixtures of 10 ug of membrane containing 5-HT2A receptor was pre-coupled to 1 mg of SPA beads at room temperature in a tube rotator for 1 hour in binding buffer (50 mM Tris-HCI pH7.4, 4 mM CaCl2, 1 mM ascorbic acid, 10 mM pargyline HCI).
- binding buffer 50 mM Tris-HCI pH7.4, 4 mM CaCl2, 1 mM ascorbic acid, 10 mM pargyline HCI.
- the beads and membrane were aliquoted in an isoplate-96 microplate with increasing amounts of [ 3 H]ketanserin (0.1525 nM to 5 nM) and incubated for two hours at room temperature in the dark with shaking.
- Tryptophan was included as a negative control as it has no activity at the 5-HT2A receptor.
- 2C-B and MDMA were used as positive controls since they are phenylalkylamine-type molecules with relatively strong (Marcher-Rorsted et al., 2020, ACS Chem. Neurosci. 11 : 1238) or more moderate (Simmler et al., 2013, British J. Pharmacol. 168: 458) 5-HT2A receptor binding activities, respectively.
- Mescaline was included as an additional positive control with established binding activity at the 5-HT2A receptor (Rickli et al., 2016, Eur. Neuropsychopharm. 26: 1327).
- Escaline and proscaline were included in this study for comparative purposes, for although their 5-HT2A receptor binding mode is understudied they are established mescaline-type hallucinogens known to induce head-twitch responses in mice (Halberstadt et al., J. Psychopharm. 33: 406). Mouse head-twitch response has been correlated with 5-HT2A receptor engagement (Halberstadt, 2015, Behav. Brain Res. 277: 99). Specific binding in counts per minute (cpm) was calculated by subtracting non-specific binding from total binding. Specific binding (pmol/mg) was calculated from pmol of [ 3 H]ketanserin bound per mg of protein in the assay.
- FIGS. 131, 13J, and 13K show the competition binding curves for 2C-B, MDMA and mescaline, respectively, as positive controls (binding).
- FIGS. 13L and 13M show the competition binding curves for escaline and proscaline, respectively, for comparative purposes.
- FIG. 13N shows the competition binding curve for tryptophan as a negative control (no binding).
- the competition binding curve for compound with formula (III), designated “(III)” in FIG. 130, reveals binding compared to the negative control.
- methyl ketone 3 (808 mg, 3.84 mmol) was dissolved in MeOH (27.1 mL) followed by the addition of acetic acid (550 pL, 9.61 mmol). The mixture was stirred for a few minutes before the addition of azetidine, 4, (545 pL, 7.69 mmol). The reaction mixture was then heated up to 60°C and stirred for 3h. At this point the reaction was cooled to RT and sodium cyanoborohydride (763 mg, 11 .5 mmol) was added to the mixture and stirring was continued at room temperature. After 18 hours, the mixture was added to a separatory funnel containing 15 mL DCM and 15 mL water. Saturated aq.
- product 8 corresponds with chemical compound (IV): set forth herein.
- FIG. 14B shows radioligand competition assay results for compound with formula (IV), depicted on the x-axis as “(IV)”. Results demonstrate receptor modulation compared to negative control.
- FIG. 14C shows radioligand competition assay results for compound with formula (IV), depicted on the x-axis as “(IV)”. Results demonstrate receptor modulation compared to negative control.
- product 6 corresponds with chemical compound (V c ): set forth herein.
- FIG. 15B shows radioligand competition assay results for compound with formula (Vc), depicted on the x-axis as “(Vc)”. Results demonstrate receptor modulation compared to negative control.
- FIG. 15C shows radioligand competition assay results for compound with formula (Vc), depicted on the x-axis as “(Vc)”. Results demonstrate no significant binding to the 5-HT2A receptor, as evidenced by a Ki value > 1000 pM.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sont divulgués de nouveaux composés dérivés de mescaline phosphorylés et sulfonés, notamment des composés dérivés de mescaline comprenant une chaîne isopropylamine ou une chaîne isopropylamine substituée, des formulations pharmaceutiques et des formulations médicamenteuses récréatives les contenant qui peuvent être utilisées dans le traitement de troubles psychiatriques. Les composés peuvent être produits par réaction d'un dérivé de mescaline précurseur avec un composé phosphoré-oxydé ou soufré-oxydé.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163291031P | 2021-12-17 | 2021-12-17 | |
US63/291,031 | 2021-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023108296A1 true WO2023108296A1 (fr) | 2023-06-22 |
Family
ID=86775234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2022/051846 WO2023108296A1 (fr) | 2021-12-17 | 2022-12-16 | Analogues d'isopropylamine de dérivés de mescaline phosphorylés et sulfonés |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023108296A1 (fr) |
-
2022
- 2022-12-16 WO PCT/CA2022/051846 patent/WO2023108296A1/fr unknown
Non-Patent Citations (5)
Title |
---|
BUZAS, A ET DUFOUR C.: "Preparation of [2-(p-hydroxyphenyl)isopropyl]methylamine", BULLETIN DE LA SOCIÉTÉ CHIMIQUE DE FRANCE, vol. 1950, 30 November 1949 (1949-11-30), France , pages 139 - 140, XP009546926, ISSN: 0037-8968 * |
ELLIS SYDNEY, ANDERSON L: "The Effect of amines on blood sugar of the rat", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 101, 14 September 1950 (1950-09-14), pages 92 - 100, XP093075991 * |
SCHWANINGER ANDREA E, MEYER MARKUS R, BARNES ALLAN J, KOLBRICH-SPARGO ERIN A, GORELICK DAVID A, GOODWIN ROBERT S, HUESTIS MARILYN : "Urinary Excretion Kinetics of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) and Its Phase I and Phase II Metabolites in Humans following Controlled MDMA Administration", CLINICAL CHEMISTRY, vol. 57, no. 12, 1 December 2011 (2011-12-01), US , pages 1748 - 1756, XP093075987, ISSN: 0009-9147, DOI: 10.1373/clinchem.2011.172254 * |
SHIMA, N. TSUTSUMI, H. KAMATA, T. NISHIKAWA, M. KATAGI, M. MIKI, A. TSUCHIHASHI, H.: "Direct determination of glucuronide and sulfate of p-hydroxymethamphetamine in methamphetamine users' urine", JOURNAL OF CHROMATOGRAPHY B, vol. 830, no. 1, 2 January 2006 (2006-01-02), NL , pages 64 - 70, XP005223425, ISSN: 1570-0232, DOI: 10.1016/j.jchromb.2005.10.014 * |
STEUER ANDREA E, SCHMIDHAUSER CORINA, SCHMID YASMIN, RICKLI ANNA, LIECHTI MATTHIAS E, KRAEMER THOMAS: "Chiral plasma pharmacokinetics of3,4-methylenedioxymethamphetamine and its phase I and II metabolites following controlled administration to humans", DRUG METABOLISM & DISPOSITION, vol. 43, no. 12, 30 November 2014 (2014-11-30), USA , pages 1864 - 1871, XP009546924, ISSN: 1521-009X, DOI: 10.1124/dmd.115.066340 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3691690B1 (fr) | Médicaments polymères programmables | |
KR101991326B1 (ko) | 오피오이드 수용체 리간드와 그 용도 및 제조방법 | |
US11845727B2 (en) | Aldehyde and ketone derivatives of psilocybin and methods of using | |
US11752130B2 (en) | Carboxylated psilocybin derivatives and methods of using | |
JP2009545594A (ja) | 改善された効能、安定性および安全性を有する疑似塩基ベンゾ[c]フェナントリジン | |
CN110092745A (zh) | 一种含芳环的化合物及其应用 | |
MX2014015249A (es) | Derivados de segunda generacion del antibiotico antifungico anfotericina b de n-sustiduidos y metodos de su preparacion y aplicacion. | |
KR102536408B1 (ko) | Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드 | |
WO2023044574A1 (fr) | Dérivés de mescaline phosphorylés et sulfonés et leurs procédés d'utilisation | |
KR20170026633A (ko) | Hiv-관련 장애의 치료 방법 및 치료용 조성물 | |
CN103073455B (zh) | 一类新型的kcnq钾通道激动剂、其制备方法和用途 | |
EA029177B1 (ru) | 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
US20240116907A1 (en) | Fused heterocyclic mescaline derivatives | |
WO2023108296A1 (fr) | Analogues d'isopropylamine de dérivés de mescaline phosphorylés et sulfonés | |
CN108640921A (zh) | 一种枸橼酸托法替布的制备方法 | |
US11707447B1 (en) | C4-carbonothioate-substituted tryptamine derivatives and methods of using | |
US11845726B2 (en) | C4-carbonothioate-substituted tryptamine derivatives and methods of using | |
CA3225135A1 (fr) | 3,4-methylenedioxymethamphetamine et composes psychedeliques apparentes et leurs utilisations | |
CA2227912A1 (fr) | Derives de benzenesulfonamide, leur preparation et leurs applications en therapeutique | |
US20240199568A1 (en) | Substituted n-propylamine fused heterocyclic mescaline derivatives | |
US20240246924A1 (en) | Substituted ethylamine fused heterocyclic mescaline derivatives | |
RU2599577C2 (ru) | Амиды n-(2-аминопурин-6-ил)-6-аминокапроновой кислоты, обладающие противоопухолевой активностью, и способ их получения | |
WO1998020013A9 (fr) | Nouveaux produits de condensation de knoevenagel, leur procede de production et leur utilisation | |
WO2024086933A1 (fr) | Dérivés de mescaline hétérocycliques fusionnés à l'isopropylamine substituée en c1 | |
WO2023173229A1 (fr) | Sels de dérivés de tryptamine à substitution acide c4-carboxylique et c4-carbonothioate et procédés d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22905600 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |